JP7414106B2 - Protein with immunoglobulin binding activity - Google Patents

Description

The present invention relates to a protein having immunoglobulin binding activity that can be used as a ligand protein for an immunoglobulin adsorbent. More specifically, the present invention relates to a protein having immunoglobulin-binding activity that can be used as a ligand protein for an immunoglobulin adsorbent that can elute antibodies under milder pH conditions than conventional immunoglobulin adsorbents.

Antibody medicines are medicines that utilize antibodies (immunoglobulins), which are molecules responsible for immune functions in living bodies. Antibody drugs bind to target molecules with high specificity and affinity due to the diversity of the antibody's variable regions. As a result, antibody drugs have few side effects, and the market for them is rapidly expanding as the range of diseases for which they are applicable has expanded in recent years.

The production of antibody drugs includes a culture process and a purification process, and in the culture process, antibody-producing cells are modified and culture conditions are optimized to improve productivity. In the purification process, affinity chromatography is employed for crude purification, followed by intermediate purification, final purification, and virus removal to form a formulation.

Affinity chromatography, which is performed as a crude purification, uses an affinity carrier that specifically recognizes antibody molecules. The ligand protein used in the carrier is Staphylococcus spp., which has the property of binding to antibodies (immunoglobulins).
Protein A derived from bacteria of the genus Ccus is often used. However, Pro
Since tein A is a protein that specifically binds to the Fc region of antibodies, it can be used for single chain Fv (scFv), Fab, F(ab') ₂ , IgA and bispecific T cell induction (
It could not be applied to the purification of antibodies that do not have an Fc region, such as antibodies (BiTE). On the other hand, F
Protein L derived from bacteria belonging to the inegoldia genus is a protein that binds to the κ light chain of immunoglobulins, so by using Protein L as a ligand protein, it is also possible to purify antibodies that do not have an Fc region, which cannot be purified with the aforementioned Protein A. becomes.

The antibody drug purification process includes a step of adsorbing antibody molecules to an affinity carrier under neutral pH conditions and then eluting the antibody molecules from the carrier under acidic pH conditions.
Since these conditions damage antibody molecules and cause aggregation, it is preferable that the pH at the time of elution is high (that is, close to neutral).

As a method to increase the antibody elution pH, there is a method of inserting an oligopeptide having flexible amino acid residues into an immunoglobulin-binding protein (Non-Patent Document 1), and a method of inserting a specific amino acid residue in an immunoglobulin-binding protein into a histidine residue. Method of substituting groups (Patent Document 1
)It has been known. However, it has been reported that the methods described in these documents reduce the chemical stability of immunoglobulin-binding proteins. Therefore, there is a need for an immunoglobulin-binding protein that has a high antibody elution pH (that is, allows antibody elution under mild pH conditions) without reducing chemical stability.

WO2019/059400

Susanne Gulich et al., Journal of Biotechnology, 2000, 76, 233-244

An object of the present invention is to provide a protein with immunoglobulin binding activity that can be used as a ligand protein for an immunoglobulin adsorbent that allows antibody elution under milder pH conditions than conventional immunoglobulin adsorbents.

As a result of intensive studies to solve the above problems, the present inventors identified amino acid residues involved in antibody elution characteristics in the immunoglobulin binding domain of Protein L (FpL) derived from Finegoldia bacteria, and The present inventors have discovered that the above problem can be solved by substituting other specific amino acid residues, and have completed the present invention.

That is, the present invention includes the following aspects:
[1]
Contains the amino acid sequence of the immunoglobulin binding domain of Protein L derived from Finegoldia bacteria, provided that the amino acid sequence contains at least the following (1) to (
11) A protein having one or more amino acid substitutions selected from the following and having immunoglobulin binding activity;
(1) The amino acid residue corresponding to the 7th lysine of SEQ ID NO: 1 is replaced with glutamine (2) The amino acid residue corresponding to the 13th lysine of SEQ ID NO: 1 is replaced with valine (3) 29 of SEQ ID NO: 1 The amino acid residue corresponding to the 6th lysine is replaced with valine or isoleucine (4) The amino acid residue corresponding to the 6th proline of SEQ ID NO: 1 is replaced with alanine (5) The 8th glutamic acid of SEQ ID NO: 1 is replaced The amino acid residue is replaced with arginine (6) The amino acid residue corresponding to the 15th asparagine in SEQ ID NO: 1 is replaced with valine (7) The amino acid residue corresponding to the 23rd isoleucine in SEQ ID NO: 1 is replaced with phenylalanine or leucine. Substitution (8) The amino acid residue corresponding to the 34th glutamic acid in SEQ ID NO: 1 is aspartic acid,
Replacement with phenylalanine, leucine, or valine (9) Replacement of the amino acid residue corresponding to lysine at position 38 of SEQ ID NO: 1 with leucine (10) Replacement of the amino acid residue corresponding to asparagine at position 50 of SEQ ID NO: 1 with methionine Substitution (11) The amino acid residue corresponding to tyrosine at position 53 of SEQ ID NO: 1 was substituted with serine.
[2]
The protein according to [1], which is a protein according to any one of the following (a) to (c):
(a) comprises the amino acid sequence set forth in SEQ ID NO: 1 or 5, provided that the amino acid sequence has at least one or more amino acid substitutions selected from (1) to (11) above;
and a protein having immunoglobulin binding activity;
(b) comprises the amino acid sequence set forth in SEQ ID NO: 1 or 5, provided that the amino acid sequence has at least one or more amino acid substitutions selected from (1) to (11) above;
Furthermore, a protein that contains substitution, deletion, insertion, and/or addition of one or several amino acid residues at one or several positions other than the above (1) to (11), and has immunoglobulin binding activity. ;
(c) Contains an amino acid sequence having 70% or more homology with the amino acid sequence set forth in SEQ ID NO: 1 or 5 or a partial sequence thereof, provided that, in the amino acid sequence, at least the above (1)
A protein having one or more amino acid substitutions selected from (11) from ) and having immunoglobulin binding activity.
[3]
Furthermore, the protein according to [1] or [2], which has at least one or more amino acid substitutions selected from the following (i) to (liii):
(i) The amino acid residue corresponding to the 50th asparagine in SEQ ID NO: 1 is replaced with tyrosine (ii) The amino acid residue corresponding to the 1st glutamic acid in SEQ ID NO: 1 is replaced with glycine or valine (iii) SEQ ID NO: 1 The amino acid residue corresponding to the 3rd proline in SEQ ID NO: 1 is replaced with serine (iv) The amino acid residue corresponding to the 4th glutamic acid in SEQ ID NO: 1 is replaced with lysine or glycine (v) The 5th glutamic acid in SEQ ID NO: 1 is replaced with lysine or glycine. The corresponding amino acid residue is replaced with valine (vi) The amino acid residue corresponding to the 7th lysine of SEQ ID NO: 1 is replaced with alanine (vii) The amino acid residue corresponding to the 8th glutamic acid of SEQ ID NO: 1 is replaced with glycine. Substitution (viii) The amino acid residue corresponding to the 9th glutamic acid in SEQ ID NO: 1 is replaced with valine (ix) The amino acid residue corresponding to the 17th isoleucine in SEQ ID NO: 1 is replaced with phenylalanine (x) The amino acid residue corresponding to the 17th isoleucine in SEQ ID NO: 1 is replaced with phenylalanine. The amino acid residue corresponding to the 21st glycine is replaced with arginine (xi) The amino acid residue corresponding to the 27th glutamic acid in SEQ ID NO: 1 is replaced with glycine or arginine (xii) Corresponds to the 29th lysine in SEQ ID NO: 1 The amino acid residue corresponding to the 31st threonine in SEQ ID NO: 1 is replaced with proline (xiii) The amino acid residue corresponding to the 36th threonine in SEQ ID NO: 1 is replaced with leucine (xiv) The amino acid residue corresponding to the 36th threonine in SEQ ID NO: 1 is replaced with alanine (xv) The amino acid residue corresponding to the 41st alanine in SEQ ID NO: 1 is replaced with threonine (xvi) The amino acid residue corresponding to the 44th asparagine in SEQ ID NO: 1 is replaced with serine or glycine (xvii) SEQ ID NO: 1 The amino acid residue corresponding to the 49th glutamic acid in SEQ ID NO: 1 is replaced with threonine or isoleucine (xviii) The amino acid residue corresponding to the 50th asparagine in SEQ ID NO: 1 is replaced with serine,
Substituted with either lysine or aspartic acid (xix) The amino acid residue corresponding to glycine at position 51 of SEQ ID NO: 1 was substituted with valine (xx) The amino acid residue corresponding to glutamic acid at position 52 of SEQ ID NO: 1 was replaced with valine, Replacement with either glycine or aspartic acid (xxi) Replacement of the amino acid residue corresponding to the 53rd tyrosine of SEQ ID NO: 1 with phenylalanine (xxii) Replacement of the amino acid residue corresponding to the 54th threonine of SEQ ID NO: 1 with isoleucine or Replaced with methionine (xxiii) The amino acid residue corresponding to asparagine at position 62 of SEQ ID NO: 1 is replaced with either histidine, arginine, leucine, methionine, or tryptophan (xxiv) The amino acid residue corresponding to asparagine at position 65 of SEQ ID NO: 1 The residue is replaced with tyrosine (xxv) The amino acid residue corresponding to the 69th alanine in SEQ ID NO: 1 is replaced with threonine (xxvi) The amino acid residue corresponding to the 2nd threonine in SEQ ID NO: 1 is replaced with serine or proline. (xxvii) The amino acid residue corresponding to the 3rd proline in SEQ ID NO: 1 is replaced with arginine (xxviii) The amino acid residue corresponding to the 5th glutamic acid in SEQ ID NO: 1 is replaced with lysine or arginine (xxix) SEQ ID NO: 1 The amino acid residue corresponding to the 27th glutamic acid in SEQ ID NO: 1 is replaced with either valine, lysine or isoleucine (xxx) The amino acid residue corresponding to the 32nd phenylalanine in SEQ ID NO: 1 is replaced with leucine (xxxi) The amino acid residue corresponding to the 38th lysine is replaced with alanine (xxxii), the amino acid residue corresponding to the 44th asparagine of SEQ ID NO: 1 is replaced with isoleucine,
(xxxiii) The amino acid residue corresponding to the 47th alanine in SEQ ID NO: 1 is replaced with threonine or arginine (xxxiv) The amino acid residue corresponding to the 52nd glutamic acid in SEQ ID NO: 1 is replaced with asparagine (xxxv) SEQ ID NO: 1 The amino acid residue corresponding to the second threonine is replaced with alanine (xxxvi) The amino acid residue corresponding to the fifth glutamic acid in SEQ ID NO: 1 is replaced with aspartic acid (xxxvii) The sixth proline in SEQ ID NO: 1 is replaced. The amino acid residue corresponding to the 7th lysine in SEQ ID NO: 1 is replaced with proline (xxxix) The amino acid residue corresponding to the 14th valine in SEQ ID NO: 1 is replaced with alanine. (xl) The amino acid residue corresponding to the 23rd isoleucine in SEQ ID NO: 1 is replaced with arginine or valine (xli) The amino acid residue corresponding to the 29th lysine in SEQ ID NO: 1 is replaced with phenylalanine (xlii) Sequence The amino acid residue corresponding to the 31st threonine in number 1 is replaced with methionine (xliii) The amino acid residue corresponding to the 33rd glutamic acid in SEQ ID NO: 1 is replaced with either aspartic acid, glycine, or valine (xliv) Sequence The amino acid residue corresponding to the 35th alanine in number 1 is replaced with threonine (xlv) The amino acid residue corresponding to the 36th threonine in SEQ ID NO: 1 is replaced with serine (xlvi) The 37th alanine in SEQ ID NO: 1 The corresponding amino acid residue is replaced with threonine (xlvii) The amino acid residue corresponding to the 41st alanine of SEQ ID NO: 1 is replaced with isoleucine or tyrosine (xlviii) The amino acid residue corresponding to the 44th asparagine of SEQ ID NO: 1 is replaced Replacement with histidine or arginine (xlviv) Replacement of the amino acid residue corresponding to the 52nd glutamic acid of SEQ ID NO: 1 with leucine or tyrosine (l) Replacement of the amino acid residue corresponding to the 60th glycine of SEQ ID NO: 1 with arginine ( li) The amino acid residue corresponding to isoleucine at position 64 of SEQ ID NO: 1 is replaced with leucine (lii) The amino acid residue corresponding to isoleucine at position 66 of SEQ ID NO: 1 is replaced with valine (liii) Position 69 of SEQ ID NO: 1 The amino acid residue corresponding to alanine is replaced with leucine or valine.
[4]
Furthermore, at least one or more lysine residues selected from the following (I) to (VII) are substituted with a basic amino acid other than lysine or an amino acid residue having a hydroxy group, [
Protein according to any one of [1] to [3]:
(I) Lysine residue corresponding to position 7 of SEQ ID NO: 1 (II) Lysine residue corresponding to position 13 of SEQ ID NO: 1 (III) Lysine residue corresponding to position 22 of SEQ ID NO: 1 (IV) SEQ ID NO: Lysine residue corresponding to position 29 of SEQ ID NO: 1 (V) Lysine residue corresponding to position 38 of SEQ ID NO: 1 (VI) Lysine residue corresponding to position 48 of SEQ ID NO: 1 (VII) Position 67 of SEQ ID NO: 1 Corresponding lysine residue.
[5]
Furthermore, substitution of the amino acid residue corresponding to the 49th glutamic acid of SEQ ID NO: 1 with aspartic acid, substitution of the amino acid residue corresponding to the 6th proline of SEQ ID NO: 1 with serine,
Substitution of the amino acid residue corresponding to the 44th asparagine of SEQ ID NO: 1 with aspartic acid, substitution of the amino acid residue corresponding to the 49th glutamic acid of SEQ ID NO: 1 with valine, and substitution of the 62nd asparagine of SEQ ID NO: 1 with valine. Substitution of the corresponding amino acid residue with tyrosine, substitution of the amino acid residue corresponding to the 23rd asparagine of SEQ ID NO: 1 with aspartic acid, and substitution of the amino acid residue corresponding to the 44th asparagine of SEQ ID NO: 1 with aspartic acid. The protein according to any one of [1] to [4], which has one or more amino acid substitutions selected from the following.
[6]
The protein according to any one of [1] to [5], having at least the following (X) or (Y) amino acid substitutions:
(X) Substitution of the amino acid residue corresponding to the fourth glutamic acid of SEQ ID NO: 1 with glycine,
Substitution of the amino acid residue corresponding to the 6th proline of SEQ ID NO: 1 with serine, substitution of the amino acid residue corresponding to the 7th lysine of SEQ ID NO: 1 with alanine, 13th and 2 of SEQ ID NO: 1
Substitution of the amino acid residues corresponding to the 2nd, 48th and 67th lysines with arginine, substitution of the amino acid residues corresponding to the 23rd isoleucine of SEQ ID NO: 1 with arginine,
Substitution of the amino acid residue corresponding to the 29th lysine of SEQ ID NO: 1 with isoleucine, substitution of the amino acid residue corresponding to the 38th lysine of SEQ ID NO: 1 with glutamic acid, corresponding to the 44th asparagine of SEQ ID NO: 1 Substitution of the amino acid residue with arginine, SEQ ID NO: 1-4
Substitution of the amino acid residue corresponding to the 9th glutamic acid with aspartic acid, substitution of the amino acid residue corresponding to the 50th and 62nd asparagine of SEQ ID NO: 1 with tyrosine, corresponding to the 53rd tyrosine of SEQ ID NO: 1 Substitution of the amino acid residue corresponding to phenylalanine and substitution of the amino acid residue corresponding to alanine at position 69 of SEQ ID NO: 1 with valine;
(Y) Substitution of the amino acid residue corresponding to the fourth glutamic acid of SEQ ID NO: 1 with glycine,
Substitution of the amino acid residue corresponding to the 6th proline of SEQ ID NO: 1 with serine, substitution of the amino acid residue corresponding to the 7th lysine of SEQ ID NO: 1 with alanine, 13th and 2 of SEQ ID NO: 1
Substitution of the amino acid residues corresponding to the 2nd and 67th lysines with arginine, substitution of the amino acid residues corresponding to the 23rd isoleucine of SEQ ID NO: 1 with arginine, SEQ ID NO: 1
Substitution of the amino acid residue corresponding to the 29th lysine with isoleucine, 38 of SEQ ID NO: 1
substitution of the amino acid residue corresponding to the 44th lysine with glutamic acid; substitution of the amino acid residue corresponding to the 44th asparagine of SEQ ID NO: 1 with arginine; substitution of the amino acid residue corresponding to the 48th lysine of SEQ ID NO: 1 with arginine; Substitution with histidine, substitution of the amino acid residue corresponding to glutamic acid at position 49 of SEQ ID NO: 1 with aspartic acid, positions 50 and 62 of SEQ ID NO: 1
Substitution of the amino acid residue corresponding to the 53rd asparagine with tyrosine, substitution of the amino acid residue corresponding to the 53rd tyrosine of SEQ ID NO: 1 with phenylalanine, substitution of the amino acid residue corresponding to the 64th isoleucine of SEQ ID NO: 1 Substitution with leucine and substitution of the amino acid residue corresponding to alanine at position 69 of SEQ ID NO: 1 with valine.
[7]
The protein according to any one of [1] to [6], comprising the amino acid sequence set forth in SEQ ID NO: 207 or 212.
[8]
A polynucleotide encoding the protein according to any one of [1] to [7].
[9]
An expression vector comprising the polynucleotide according to [8].
[10]
A genetically modified host comprising the following (A) or (B):
(A) a polynucleotide encoding the protein according to any one of [1] to [7];
(B) An expression vector comprising a polynucleotide encoding the protein according to any one of [1] to [7].
[11]
The genetically modified host according to [10], wherein the host is Escherichia coli.
[12]
A step of culturing a genetically recombinant host containing a polynucleotide encoding the protein according to any one of [1] to [7] or an expression vector containing the polynucleotide to express the protein; A method for producing an immunoglobulin-binding protein, the method comprising the step of recovering the expressed protein.
[13]
The production method according to [12], wherein the host is Escherichia coli.
[14]
An immunoglobulin adsorbent comprising an insoluble carrier and the protein according to any one of [1] to [7] immobilized on the insoluble carrier.
[15]
A step of adding a solution containing immunoglobulin to the column packed with the adsorbent described in [14] to adsorb the immunoglobulin to the adsorbent, and a step of eluting the immunoglobulin adsorbed to the adsorbent by changing the pH. A method for separating immunoglobulins contained in the solution, comprising:
[16]
The method according to [15], wherein the pH change is a decrease in pH.

The protein of the present invention comprises the amino acid sequence of the immunoglobulin-binding domain of protein L derived from the genus Finegoldia, but has at least one amino acid substitution in the amino acid sequence that improves antibody elution properties, and has immunoglobulin-binding activity. It is characterized by having According to the immunoglobulin adsorbent of the present invention, which includes an insoluble carrier and the protein of the present invention immobilized on the insoluble carrier, immunoglobulin (antibody) can be eluted under mild pH conditions compared to conventional immunoglobulin adsorbents. As a result, high quality immunoglobulin can be obtained.

The present invention will be explained in detail below.

The proteins of the invention are specific immunoglobulin binding proteins. As used herein, the term "immunoglobulin-binding protein" refers to a protein that has the ability to bind to immunoglobulins. That is, the protein of the present invention has binding properties to specific immunoglobulins. Specifically, the protein of the present invention may have the ability to bind to the κ light chain of immunoglobulin. In this specification, binding to immunoglobulin is also referred to as "immunoglobulin binding activity" or "antibody binding activity." Immunoglobulin binding activity can be measured, for example, by ELISA (Enzyme-Linked ImmunoSorbent).
It can be measured by the Assay method. The ELISA method can be carried out, for example, under the conditions described in the Examples.

The protein of the present invention is Protein L (“Fp
It is a protein that contains the amino acid sequence of the immunoglobulin-binding domain of the immunoglobulin-binding domain (also referred to as "L"), but has amino acid substitutions at specific positions in the amino acid sequence. Hereinafter, in this specification, the amino acid sequence of the immunoglobulin-binding domain of FpL that does not have amino acid substitutions at specific positions is also referred to as the "unmodified amino acid sequence", and the amino acid sequence of the immunoglobulin-binding domain of FpL A sequence having an amino acid substitution at a specific position is also referred to as a "modified amino acid sequence." That is, the modified amino acid sequence may be the same amino acid sequence as the non-modified amino acid sequence except for having an amino acid substitution at a specific position. Furthermore, the protein of the present invention may be, for example, a protein that includes an amino acid sequence that is the same as an unmodified amino acid sequence except for having an amino acid substitution at a specific position. Furthermore, the protein of the present invention may be, for example, a protein containing a modified amino acid sequence. The unmodified amino acid sequence may or may not be an amino acid sequence found in nature. An unmodified amino acid sequence may be modified to have desired properties, for example. The unmodified amino acid sequence may have, for example, amino acid substitutions other than amino acid substitutions at specific positions.

The Finegoldia bacteria from which FpL is derived include Finegoldia m.
Examples include agna. The immunoglobulin binding domain of Finegoldia magna-derived Protein L is as follows:
Domain B1 (amino acid residues from 104th to 173rd of SEQ ID NO: 38 (GenBank No. AAA25612)),
Domain B2 (amino acid residues from position 176 to position 245 of SEQ ID NO: 38),
Domain B3 (amino acid residues from position 248 to position 317 of SEQ ID NO: 38),
Domain B4 (amino acid residues from position 320 to position 389 of SEQ ID NO: 38),
Domain B5 (amino acid residues from position 393 to position 462 of SEQ ID NO: 38),
Domain C1 (amino acid residues from 249th to 317th of SEQ ID NO: 39 (GenBank No. AAA67503)),
Domain C2 (amino acid residues from position 320 to position 389 of SEQ ID NO: 39),
Examples include domain C3 (amino acid residues 394th to 463rd of SEQ ID NO: 39: SEQ ID NO: 1) and domain C4 (amino acid residues 468th to 537th of SEQ ID NO: 39: SEQ ID NO: 5).

As used herein, the unmodified amino acid sequence is
(A) It may be the entire amino acid sequence of the above-mentioned immunoglobulin binding domain of FpL,
(B) It may be a partial amino acid sequence of the domain as long as it has immunoglobulin-binding activity.

Regarding (B) above, the immunoglobulin-binding domain of FpL is composed of four β-sheets, one α-helix, a loop connecting them, and an N-terminal loop region. Amino acid residues in regions unrelated to binding to may be deleted. As a specific example, even if the amino acid residues from the 1st glutamic acid to the 9th glutamic acid, which correspond to the N-terminal loop region of domain C3 (SEQ ID NO: 1) of FpL, are deleted, it still has immunoglobulin binding ability. It is known that (Housden N.
G. etc. al. Biochemical Society Transaction,
2003, 31, 716-718). That is, it is sufficient that the partial amino acid sequence in (B) above includes at least the amino acid sequence of the binding site to immunoglobulin.
That is, the partial amino acid sequence in (B) above includes a partial sequence including the amino acid sequence of a binding site to immunoglobulin.

The modified amino acid sequence herein specifically includes an amino acid sequence having an amino acid substitution at a specific position in the amino acid sequence of the immunoglobulin binding domain described above, such as the amino acid sequence set forth in SEQ ID NO: 1. That is, the protein of the present invention specifically includes a protein that includes the above-described amino acid sequence of the immunoglobulin binding domain, such as the amino acid sequence set forth in SEQ ID NO: 1, but has an amino acid substitution at a specific position in the amino acid sequence. Can be mentioned. In other words, the protein of the present invention is a protein that includes an amino acid sequence that is identical to the amino acid sequence of the immunoglobulin binding domain described above, such as the amino acid sequence set forth in SEQ ID NO: 1, except for having an amino acid substitution at a specific position. It's fine.

In this specification, the fact that a protein includes an amino acid sequence is also referred to as "the protein contains amino acid residues consisting of an amino acid sequence", and the fact that a protein or amino acid sequence has an amino acid substitution is also referred to as "an amino acid substitution in a protein or amino acid sequence". will occur.”
Also called. Also, the amino acids that make up a protein or amino acid sequence are called "amino acid residues".
Also called.

The protein of the present invention may be an immunoglobulin-binding protein that allows antibody elution under mild pH conditions. Specifically, the protein of the present invention is an immunoglobulin-binding protein that allows antibody elution under mild pH conditions compared to an immunoglobulin-binding protein that does not have a modified amino acid sequence (for example, consists of an unmodified amino acid sequence). It may be a natural protein. Specifically, the protein of the present invention may be an immunoglobulin-binding protein that allows antibody elution under mild pH conditions compared to immunoglobulin-binding proteins that do not have amino acid substitutions at specific positions. In other words, the protein of the present invention may be an immunoglobulin-binding protein that has amino acid substitutions at specific positions and thus enables antibody elution under mild pH conditions. In other words, amino acid substitution at a specific position is
It may be possible to elute antibodies from immunoglobulin-binding proteins under mild pH conditions.

"Mild pH conditions" may mean pH conditions close to neutrality. That is, "antibody elution is possible under mild conditions" may mean that antibody elution is possible under near-neutral pH conditions. Furthermore, since typical antibody elution pH can be acidic, "antibody elution is possible under mild conditions" may mean that the antibody elution pH is increased. The elution pH of the antibody is
For example, it can be measured under the conditions described in Examples.

Specifically, the amino acid substitution at the specific position is Lys7Gln (this notation indicates that the amino acid residue corresponding to the 7th lysine in SEQ ID NO: 1 is substituted with glutamine; hereinafter, other amino acid substitutions shall be interpreted in the same manner), Lys13Va
l, Lys29Val, Lys29Ile, Pro6Ala, Glu8Arg, Asn1
5Val, Ile23Phe, Ile23Leu, Glu34Asp, Glu34Phe
, Glu34Leu, Glu34Val, Lys38Leu, Asn50Met and T
Contains at least one or more amino acid substitutions selected from yr53Ser.

In other words, the amino acid substitution at the specific position is at least
(1) Lys7Gln
(2) Lys13Val
(3) Lys29Val or Lys29Ile
(4) Pro6Ala
(5) Glu8Arg
(6) Asn15Val
(7) Ile23Phe or Ile23Leu
(8) Glu34Asp, Glu34Phe, Glu34Leu and Glu34Val
Any (9) Lys38Leu
(10) Asn50Met
(11) Tyr53Ser
one or more amino acid substitutions selected from The protein of the present invention is, for example, the above (
may have one, two, three, four, five, six, seven, eight or nine amino acid substitutions selected from 1) to (11), or 10 or more amino acids May have substitutions.

In addition, when the protein of the present invention has two or more amino acid substitutions, the combination of these amino acid substitutions is particularly suitable as long as it includes at least one or more amino acid substitutions selected from (1) to (11) above. Not restricted.

As one aspect of the combination of amino acid substitutions,
Amino acid substitutions in Pro6Ala and Lys29Ile;
Amino acid substitutions of Glu8Arg and Lys29Ile;
Amino acid substitutions of Ile23Phe and Lys29Ile;
Amino acid substitutions of Ile23Leu and Lys29Ile;
Amino acid substitutions of Lys29Ile and Lys38Leu;
Amino acid substitutions of Lys29Ile and Asn50Met;
Amino acid substitutions of Lys59Ile and Tyr53Ser;
Amino acid substitutions of Asn15Val and Lys29Ile;
Amino acid substitutions in Lys29Ile and Glu34Asp;
Amino acid substitutions of Lys29Ile and Glu34Phe;
Amino acid substitutions of Lys29Ile and Glu34Leu;
Amino acid substitutions of Lys29Ile and Glu34Val;
can be given.

Furthermore, the amino acid substitution at the specific position may further include one or more amino acid substitutions selected from (i) to (liii) below. That is, as another embodiment of the combination of amino acid substitutions that the protein of the present invention has, at least the above (1) to (11)
Also included is a combination of one or more amino acid substitutions selected from the above and one or more amino acid substitutions selected from at least the following (i) to (liii).
(i) The amino acid residue corresponding to the 50th asparagine in SEQ ID NO: 1 is replaced with tyrosine (
ii) The amino acid residue corresponding to the first glutamic acid in SEQ ID NO: 1 is replaced with glycine or valine. (iii) The amino acid residue corresponding to the third proline in SEQ ID NO: 1 is replaced with serine. (iv) The amino acid residue corresponding to the third proline in SEQ ID NO: 1 is replaced with serine. The amino acid residue corresponding to the 4th glutamic acid is replaced with lysine or glycine (v) The amino acid residue corresponding to the 5th glutamic acid in SEQ ID NO: 1 is replaced with valine (vi) Corresponds to the 7th lysine in SEQ ID NO: 1 (vii) The amino acid residue corresponding to the 8th glutamic acid in SEQ ID NO: 1 is replaced with glycine (viii) The amino acid residue corresponding to the 9th glutamic acid in SEQ ID NO: 1 is replaced with valine. (ix) The amino acid residue corresponding to the 17th isoleucine in SEQ ID NO: 1 is replaced with phenylalanine (x) The amino acid residue corresponding to the 21st glycine in SEQ ID NO: 1 is replaced with arginine (xi) 27 in SEQ ID NO: 1 The amino acid residue corresponding to the 29th glutamic acid is replaced with glycine or arginine (xii) The amino acid residue corresponding to the 29th lysine of SEQ ID NO: 1 is replaced with proline (xiii) The 31st threonine of SEQ ID NO: 1 is replaced The amino acid residue is replaced with leucine (xiv) The amino acid residue corresponding to the 36th threonine in SEQ ID NO: 1 is replaced with alanine (xv) The amino acid residue corresponding to the 41st alanine in SEQ ID NO: 1 is replaced with threonine ( xvi) The amino acid residue corresponding to asparagine at position 44 of SEQ ID NO: 1 is replaced with serine or glycine (xvii) The amino acid residue corresponding to glutamic acid at position 49 of SEQ ID NO: 1 is replaced with threonine or isoleucine (xviii) SEQ ID NO: The amino acid residue corresponding to the 50th asparagine in 1 is serine,
Substituted with either lysine or aspartic acid (xix) The amino acid residue corresponding to glycine at position 51 of SEQ ID NO: 1 was substituted with valine (xx) The amino acid residue corresponding to glutamic acid at position 52 of SEQ ID NO: 1 was replaced with valine, Replacement with either glycine or aspartic acid (xxi) Replacement of the amino acid residue corresponding to the 53rd tyrosine of SEQ ID NO: 1 with phenylalanine (xxii) Replacement of the amino acid residue corresponding to the 54th threonine of SEQ ID NO: 1 with isoleucine or Replaced with methionine (xxiii) The amino acid residue corresponding to asparagine at position 62 of SEQ ID NO: 1 is replaced with either histidine, arginine, leucine, methionine, or tryptophan (xxiv) The amino acid residue corresponding to asparagine at position 65 of SEQ ID NO: 1 The residue is replaced with tyrosine (xxv) The amino acid residue corresponding to the 69th alanine in SEQ ID NO: 1 is replaced with threonine (xxvi) The amino acid residue corresponding to the 2nd threonine in SEQ ID NO: 1 is replaced with serine or proline. (xxvii) The amino acid residue corresponding to the 3rd proline in SEQ ID NO: 1 is replaced with arginine (xxviii) The amino acid residue corresponding to the 5th glutamic acid in SEQ ID NO: 1 is replaced with lysine or arginine (xxix) SEQ ID NO: 1 The amino acid residue corresponding to the 27th glutamic acid in SEQ ID NO: 1 is replaced with either valine, lysine or isoleucine (xxx) The amino acid residue corresponding to the 32nd phenylalanine in SEQ ID NO: 1 is replaced with leucine (xxxi) The amino acid residue corresponding to the 38th lysine is replaced with alanine (xxxii), the amino acid residue corresponding to the 44th asparagine of SEQ ID NO: 1 is replaced with isoleucine,
(xxxiii) The amino acid residue corresponding to the 47th alanine in SEQ ID NO: 1 is replaced with threonine or arginine (xxxiv) The amino acid residue corresponding to the 52nd glutamic acid in SEQ ID NO: 1 is replaced with asparagine (xxxv) SEQ ID NO: 1 The amino acid residue corresponding to the second threonine is replaced with alanine (xxxvi) The amino acid residue corresponding to the fifth glutamic acid in SEQ ID NO: 1 is replaced with aspartic acid (xxxvii) The sixth proline in SEQ ID NO: 1 is replaced. The amino acid residue corresponding to the 7th lysine in SEQ ID NO: 1 is replaced with proline (xxxix) The amino acid residue corresponding to the 14th valine in SEQ ID NO: 1 is replaced with alanine. (xl) The amino acid residue corresponding to the 23rd isoleucine in SEQ ID NO: 1 is replaced with arginine or valine (xli) The amino acid residue corresponding to the 29th lysine in SEQ ID NO: 1 is replaced with phenylalanine (xlii) Sequence The amino acid residue corresponding to the 31st threonine in number 1 is replaced with methionine (xliii) The amino acid residue corresponding to the 33rd glutamic acid in SEQ ID NO: 1 is replaced with either aspartic acid, glycine, or valine (xliv) Sequence The amino acid residue corresponding to the 35th alanine in number 1 is replaced with threonine (xlv) The amino acid residue corresponding to the 36th threonine in SEQ ID NO: 1 is replaced with serine (xlvi) The 37th alanine in SEQ ID NO: 1 The corresponding amino acid residue is replaced with threonine (xlvii) The amino acid residue corresponding to the 41st alanine of SEQ ID NO: 1 is replaced with isoleucine or tyrosine (xlviii) The amino acid residue corresponding to the 44th asparagine of SEQ ID NO: 1 is replaced with isoleucine or tyrosine (xlviii) Replacement with histidine or arginine (xlviv) Replacement of the amino acid residue corresponding to the 52nd glutamic acid of SEQ ID NO: 1 with leucine or tyrosine (l) Replacement of the amino acid residue corresponding to the 60th glycine of SEQ ID NO: 1 with arginine ( li) The amino acid residue corresponding to isoleucine at position 64 of SEQ ID NO: 1 is replaced with leucine (lii) The amino acid residue corresponding to isoleucine at position 66 of SEQ ID NO: 1 is replaced with valine (liii) Position 69 of SEQ ID NO: 1 The amino acid residue corresponding to alanine is replaced with leucine or valine.

Note that among the amino acid substitutions (i) to (liii) above, amino acid substitutions at the same position are not selected at the same time. For example, the amino acid substitution (iii) above and the amino acid substitution (xxvii) above are not selected at the same time.

In one aspect, the amino acid substitution at the specific position is in (i) to (liii) above.
may contain one or more amino acid substitutions selected from

One or more amino acid substitutions selected from (1) to (11) above and (i) to (l)
The protein of the present invention having a combination with one or more amino acid substitutions selected from iii) is preferred in that the alkali stability can also be improved. In particular, the protein of the present invention having a combination of one or more amino acid substitutions selected from (1) to (11) above and at least the amino acid substitution (i) above can be used for antibody elution under mild pH conditions. It is more preferable because it is possible to do this and has improved alkali stability.

"Alkaline stability" may mean resistance to deactivation in alkaline conditions. Improved alkali stability can be measured, for example, as an increase in residual activity after alkali treatment. "Activity" here means immunoglobulin binding activity. Alkaline treatment is, for example,
It can be carried out under the conditions described in the Examples.

The protein of the present invention has, for example, one, two, three, four, five, six, seven, eight or nine amino acid substitutions selected from the amino acid substitutions described in (i) to (liii) above. It may have one amino acid substitution, or it may have ten or more amino acid substitutions. The protein of the present invention is
For example, it may have at least the amino acid substitution described in (i) above. however,
(1) If Lys7Gln amino acid substitution is selected, the above (vi) and the above (xx
xviii) amino acid substitution cannot be selected,
(3) If Lys29Val or Lys29Ile amino acid substitution is selected, the above (xii) and above (xli) amino acid substitutions cannot be selected,
(4) If the amino acid substitution of Pro6Ala is selected, the amino acid substitution of (xxxvii) above cannot be selected,
(5) If the amino acid substitution of Glu8Arg is selected, the amino acid substitution of (vii) above cannot be selected,
(7) If the amino acid substitution of Ile23Phe or Ile23Leu is selected, the amino acid substitution of (xl) above cannot be selected,
(9) When choosing the amino acid substitution of Lys38Leu, the above (i) and the above (xx
xi) Amino acid substitution cannot be selected,
(10) If the amino acid substitution of Asp50Met is selected, the amino acid substitution of (xviii) above cannot be selected,
(11) If the Tyr53Ser amino acid substitution is selected, the amino acid substitution (xxi) above cannot be selected.

As a specific example of another embodiment of the combination of amino acid substitutions,
Amino acid substitutions of Lys7Ala and Lys29Ile;
Amino acid substitutions of Lys7Ala, Lys29Ile, Asn50Tyr and Glu52Gly;
Lys7Ala, Glu9Val, Lys29Ile, Asn50Tyr and Glu5
Amino acid substitution of 2Gly;
Lys7Ala, Lys29Ile, Asn50Tyr, Glu52Gly and Tyr
Amino acid substitution of 53Phe;
Lys7Ala, Lys29Ile, Asn50Tyr, Glu52Gly and Thr
Amino acid substitution of 54Met;
Lys7Ala, Lys29Ile, Asn50Tyr, Glu52Gly and Ala
Amino acid substitution at 69Thr;
Glu1Val, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52G
Amino acid substitutions of ly and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52G
Amino acid substitutions of ly and Tyr53Phe;
Amino acid substitutions of Lys29Ile, Asn50Tyr, Glu52Gly and Tyr53Phe;
Lys7Ala, Gly21Arg, Lys29Ile, Asn50Tyr, Glu52
Gly and Tyr53Phe amino acid substitutions;
Lys7Ala, Lys29Ile, Asn50Tyr, Glu52Asp and Tyr
Amino acid substitution of 53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52A
sp and Tyr53Phe amino acid substitutions;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52A
sp, Tyr53Phe and Ala69Val amino acid substitutions;
Glu4Gly, Lys7Ala, Glu8Gly, Lys29Ile, Glu33Va
l, Asn50Tyr, Glu52Asp and Tyr53Phe amino acid substitutions;
Glu4Gly, Lys7Ala, Ile23Arg, Lys29Ile, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Ala41Ile, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Ala41Tyr, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52L
Amino acid substitution of eu and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52V
Amino acid substitutions of al and Tyr53Phe;
Glu4Gly, Pro6Ala, Lys7Ala, Lys29Ile, Asn50Ty
r, Glu52Asp and Tyr53Phe amino acid substitutions;
Glu4Gly, Lys7Ala, Glu8Gly, Lys29Ile, Asn50Ty
r, Glu52Asp and Tyr53Phe amino acid substitutions;
Glu4Gly, Lys7Ala, Glu8Arg, Lys29Ile, Asn50Ty
r, Glu52Asp and Tyr53Phe amino acid substitutions;
Glu4Gly, Lys7Ala, Gly21Arg, Lys29Ile, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Ile23Phe, Lys29Ile, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Ile23Leu, Lys29Ile, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Glu33Val, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Lys38Leu, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn44His, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn44Arg, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Lys48His, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Met, Glu52A
sp and Tyr53Phe amino acid substitutions;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52T
Amino acid substitutions of yr and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52A
sp and Tyr53Ser amino acid substitutions;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52V
amino acid substitutions of al, Tyr53Phe and Ala67Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52L
Amino acid substitutions of eu, Tyr53Phe and Ala67Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Tyr53P
Amino acid substitution of he and Ala67Val;
Glu4Gly, Lys7Ala, Val14Ala, Lys29Ile, Asn50T
Amino acid substitutions of yr, Tyr53Phe and Ala67Val;
Glu4Gly, Lys7Ala, Gly21Arg, Lys29Ile, Asn50T
Amino acid substitutions of yr, Tyr53Phe and Ala67Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn44Arg, Asn50T
Amino acid substitutions of yr, Tyr53Phe and Ala67Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn44His, Asn50T
Amino acid substitutions of yr, Tyr53Phe and Ala67Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Glu52T
Amino acid substitutions of yr, Tyr53Phe and Ala67Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Tyr53P
amino acid substitutions of he, Gly60Arg and Ala67Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn50Tyr, Tyr53P
amino acid substitutions of he, Ile64Leu and Ala67Val;
Glu4Gly, Lys7Ala, Ile23Arg, Lys29Ile, Asn44A
rg, Asn50Tyr, Tyr53Phe and Ala69Val amino acid substitutions;
Glu4Gly, Lys7Ala, Ile23Arg, Lys29Ile, Asn44H
is, Asn50Tyr, Tyr53Phe and Ala69Val amino acid substitutions;
Glu4Gly, Lys7Ala, Ile23Arg, Lys29Ile, Asn50T
Amino acid substitutions of yr, Tyr53Phe, Ile64Leu and Ala69Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn44Arg, Asn50T
Amino acid substitutions of yr, Tyr53Phe, Ile64Leu and Ala69Val;
Glu4Gly, Lys7Ala, Lys29Ile, Asn44His, Asn50T
Amino acid substitutions of yr, Tyr53Phe, Ile64Leu and Ala69Val;
Glu4Gly, Lys7Ala, Ile23Arg, Lys29Ile, Asn44A
rg, Asn50Tyr, Tyr53Phe, Ile64Leu and Ala69Val
Amino acid substitution of;
Glu4Gly, Lys7Ala, Lys29Ile, Asn44His, Asn50T
Amino acid substitutions of yr, Tyr53Phe, Ile64Leu and Ala69Val;
Glu4Gly, Lys7Ala, Asn15Val, Lys29Ile, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Glu34Asp, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Glu34Phe, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Glu34Leu, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
Glu4Gly, Lys7Ala, Lys29Ile, Glu34Val, Asn50T
Amino acid substitutions of yr, Glu52Asp and Tyr53Phe;
can be given.

In addition, the amino acid substitution at the specific position may further include basic amino acids other than lysine (arginine (Arg) or histidine (Lys)) of one or more lysine (Lys) residues selected from (I) to (VII) below. (His)) or an amino acid having a hydroxy group (serine (Ser), threonine (Thr) or tyrosine (Tyr)). That is, as yet another embodiment of the combination of amino acid substitutions that the protein of the present invention has, at least one or more amino acid substitutions selected from (1) to (11) above, and at least the following (I) to (VII) one or more lysines (Lys) selected from
) residues of basic amino acids other than lysine (arginine (Arg) or histidine (Hi
s)) or amino acids with hydroxy groups (serine (Ser), threonine (Thr)
Alternatively, a combination with substitution with tyrosine (Tyr) may also be mentioned.
(I) Lysine residue corresponding to position 7 of SEQ ID NO: 1 (II) Lysine residue corresponding to position 13 of SEQ ID NO: 1 (III) Lysine residue corresponding to position 22 of SEQ ID NO: 1 (IV) SEQ ID NO: Lysine residue corresponding to position 29 of SEQ ID NO: 1 (V) Lysine residue corresponding to position 38 of SEQ ID NO: 1 (VI) Lysine residue corresponding to position 48 of SEQ ID NO: 1 (VII) Position 67 of SEQ ID NO: 1 Corresponding lysine residue

The proteins of the present invention include one, two, three selected from (I) to (VII) above,
may have substitutions of 4, 5 or 6 lysine residues, further comprising (i) to (lii)
i) may have one or more amino acid substitutions selected from however,
(1) If the Lys7Gln amino acid substitution is selected, the above (I) lysine residue substitution cannot be selected,
(2) If the amino acid substitution of Lys13Val is selected, the substitution of the lysine residue in (II) above cannot be selected,
(3) If Lys29Val or Lys29Ile amino acid substitution is selected, the above (IV) lysine residue substitution cannot be selected,
(9) If the amino acid substitution of Lys38Leu is selected, the substitution of the lysine residue in (V) above cannot be selected.

In addition, regarding lysine residues other than lysine residues substituted with basic amino acids or amino acids having a hydroxyl group (i.e., those not selected from the lysine residues in (I) to (VII) above), It may remain unsubstituted (lysine residue) or may be substituted with an amino acid other than a basic amino acid or an amino acid having a hydroxyl group. Examples of the latter include substitution of lysine residues with glutamine or isoleucine, and the above-mentioned Lys13Val, Lys
Includes amino acid substitutions of s29Val and Lys38Leu.

As a specific example of yet another embodiment of the combination of amino acid substitutions,
Lys7Gln, Lys13Arg, Lys22Arg, Lys29Arg, Lys48
Amino acid substitution of Arg and Lys67Arg;
Lys7Arg, Lys13Val, Lys22Arg, Lys29Arg, Lys48
Amino acid substitution of Arg and Lys67Arg;
Lys7Arg, Lys13Arg, Lys22Arg, Lys29Val, Lys48
Amino acid substitution of Arg and Lys67Arg;
Lys7Arg, Lys13Arg, Lys22Arg, Lys29Ile, Lys48
Amino acid substitution of Arg and Lys67Arg;
can be given.

Furthermore, the amino acid substitution at the specific position includes one or more amino acid substitutions selected from (i) to (liii) above and one or more lysine (Lys) residues selected from (I) to (VII) above. It may also include a combination with substitution of a basic amino acid other than lysine or an amino acid having a hydroxy group. That is, as yet another embodiment of the combination of amino acid substitutions that the protein of the present invention has, at least the above (1) to (11)
one or more amino acid substitutions selected from at least one of the above (i) to (liii), and one or more amino acid substitutions selected from at least the above (I) to (VII). Also included is a combination of substitution of a lysine (Lys) residue with a basic amino acid other than lysine or an amino acid having a hydroxy group.

Specific examples of yet another combination of amino acid substitutions include Lys7Ala, Lys13Arg, Lys29Ile, Lys38Arg, Lys48
Amino acid substitution of Arg and Lys67Arg;
Lys7Ala, Lys13Arg, Lys29Ile, Lys38Arg, Lys48
Amino acid substitutions of Arg, Asn50Tyr, Glu52Gly and Lys67Arg;
Lys7Ala, Glu9Val, Lys29Ile, Lys38Arg, Lys48A
rg, Asn50Tyr, Glu52Gly and Lys67Arg amino acid substitutions;
Lys7Ala, Lys13Arg, Lys22Arg, Lys29Ile, Lys38
Arg, Lys48Arg, Asn50Tyr, Glu52Gly and Lys67Ar
Amino acid substitution of g;
Lys7Ala, Lys13Arg, Lys29Ile, Lys38Arg, Lys48
Arg, Asn50Tyr, Glu52Gly, Tyr53Phe and Lys67Ar
Amino acid substitution of g;
Lys7Ala, Lys13Arg, Lys29Ile, Lys38Arg, Lys48
rg, Asn50Tyr, Glu52Gly, Thr54Met and Lys67Arg
Amino acid substitution of;
Lys7Ala, Lys13Arg, Lys29Ile, Lys38Arg, Lys48
rg, Asn50Tyr, Glu52Gly, Lys67Arg and Ala69Thr
Amino acid substitution of;
Lys7Ala, Lys13Arg, Lys22Arg, Lys29Ile, Lys38
Amino acid substitutions of Arg, Lys48Arg, Asn50Tyr, Glu52Gly, Tyr53Phe and Lys67Arg;
Glu1Val, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys38Arg, Lys48Arg, Asn50Tyr, Glu52Gly, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys38Arg, Lys48Arg, Asn50Tyr, Glu52Gly, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Lys7Ser, Lys13Arg, Lys22Arg, Lys29Ile, Lys38
Amino acid substitutions of Arg, Lys48Arg, Asn50Tyr, Glu52Gly, Tyr53Phe and Lys67Arg;
Lys7Ala, Lys13Arg, Gly21Arg, Lys22Arg, Lys29
Ile, Lys38Arg, Lys48Arg, Asn50Tyr, Glu52Gly,
Amino acid substitutions of Tyr53Phe and Lys67Arg;
Lys7Ala, Lys13Arg, Lys22Arg, Lys29Ile, Lys38
Amino acid substitutions of Arg, Lys48Arg, Asn50Tyr, Glu52Asp, Tyr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
amino acid substitutions of le, Lys48Arg, Asn50Tyr, Glu52Asp, Tyr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys48Arg, Asn50Tyr, Glu52Asp, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Glu8Gly, Lys13Arg, Lys22Ar
g, Lys29Ile, Glu33Val, Lys48Arg, Asn50Tyr, Gl
Amino acid substitutions of u52Asp, Tyr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Ile23A
rg, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Ala41Ile, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Ala41Tyr, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
amino acid substitutions of le, Lys48Arg, Asn50Tyr, Glu52Leu, Tyr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
amino acid substitutions of le, Lys48Arg, Asn50Tyr, Glu52Val, Tyr53Phe and Lys67Arg;
Glu4Gly, Pro6Ala, Lys7Ala, Lys13Arg, Lys22Ar
g, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, Ty
Amino acid substitutions of r53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Glu8Gly, Lys13Arg, Lys22Ar
g, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, Ty
Amino acid substitutions of r53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Glu8Arg, Lys13Arg, Lys22Ar
g, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, Ty
Amino acid substitutions of r53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Gly21Arg, Lys22A
rg, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Ile23P
he, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Ile23L
eu, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Glu33Val, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys38His, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys38Leu, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44His, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44Arg, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44His, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
amino acid substitutions of le, Lys48Arg, Asn50Met, Glu52Asp, Tyr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
amino acid substitutions of le, Lys48Arg, Asn50Tyr, Glu52Tyr, Tyr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
amino acid substitutions of le, Lys48Arg, Asn50Tyr, Glu52Asp, Tyr53Ser and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys48Arg, Asn50Tyr, Glu52Val, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys48Arg, Asn50Tyr, Glu52Leu, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
amino acid substitutions of le, Lys48Arg, Asn50Tyr, Tyr53Phe, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Val14Ala, Lys22A
rg, Lys29Ile, Lys48Arg, Asn50Tyr, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Gly21Arg, Lys22A
rg, Lys29Ile, Lys48Arg, Asn50Tyr, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44Arg, Lys48Arg, Asn50Tyr, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44His, Lys48Arg, Asn50Tyr, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys48Arg, Asn50Tyr, Glu52Tyr, Tyr53Phe, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys48Arg, Asn50Tyr, Tyr53Phe, Gly60Arg, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Lys48Arg, Asn50Tyr, Tyr53Phe, Ile64Leu, L
Amino acid substitutions of ys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Ile23A
rg, Lys29Ile, Asn44Arg, Lys48Arg, Asn50Tyr, T
Amino acid substitutions of yr53Phe, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Ile23A
rg, Lys29Ile, Asn44His, Lys48Arg, Asn50Tyr, T
Amino acid substitutions of yr53Phe, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Ile23A
rg, Lys29Ile, Lys48Arg, Asn50Tyr, Tyr53Phe, I
Amino acid substitutions of le64Leu, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44Arg, Lys48Arg, Asn50Tyr, Tyr53Phe, I
Amino acid substitutions of le64Leu, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44His, Lys48Arg, Asn50Tyr, Tyr53Phe, I
Amino acid substitutions of Ile64Leu, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Ile23A
rg, Lys29Ile, Asn44Arg, Lys48His, Asn50Tyr, T
Amino acid substitutions of yr53Phe, Ile64Leu, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Asn44His, Lys48His, Asn50Tyr, Tyr53Phe, I
Amino acid substitutions of le64Leu, Lys67Arg and Ala69Val;
Glu4Gly, Lys7Ala, Lys13Arg, Asn15Val, Lys22A
rg, Lys29Ile, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Glu34Asp, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Glu3Phe, Lys48Arg, Asn50Tyr, Glu52Asp, Ty
Amino acid substitutions of r53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Glu34Leu, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
Glu4Gly, Lys7Ala, Lys13Arg, Lys22Arg, Lys29I
le, Glu34Val, Lys48Arg, Asn50Tyr, Glu52Asp, T
Amino acid substitutions of yr53Phe and Lys67Arg;
can be given.

Note that the protein of the present invention may further have at least one other amino acid substitution. Other amino acid substitutions include Glu49Asp, Pro6Ser, Asn44Asp
, Glu49Val, Asn62Tyr, Ile23Thr, and Ala41Arg. Other amino acid substitutions may, for example, improve the alkaline stability of the immunoglobulin binding protein. For example, Asn44Asp, Glu49Val, Asn
The amino acid substitutions of 62Tyr, Ile23Thr, and Ala41Arg are all
It may improve the alkaline stability of immunoglobulin binding proteins. The protein of the invention may have, for example, one, two, three, four, five, or six of the other amino acid substitutions. That is, examples of modified amino acid sequences include amino acid sequences having amino acid substitutions at the specific positions and other amino acid substitutions such as Glu49Asp and Pro6Ser in the non-modified amino acid sequences exemplified above (for example, the amino acid sequence set forth in SEQ ID NO: 1). It will be done. That is, the protein of the present invention includes the unmodified amino acid sequence exemplified above (for example, the amino acid sequence set forth in SEQ ID NO: 1), but in the amino acid sequence, amino acid substitutions at the specific positions and Glu49Asp and Pro6Ser
Also included are proteins with other amino acid substitutions, such as. In other words, the protein of the present invention includes, for example, amino acid substitutions at the specific positions and Glu49Asp and Pro6.
It may be a protein containing the same amino acid sequence as the unmodified amino acid sequence exemplified above (for example, the amino acid sequence set forth in SEQ ID NO: 1) except for having other amino acid substitutions such as Ser. In addition, Glu49Asp and Pro6Ser, which were exemplified as other amino acid substitutions,
is an amino acid substitution that can bind to the kappa light chain of immunoglobulins regardless of subgroup.

The combinations of amino acid substitutions including the other amino acid substitutions include 1, 2, 3, 4, 5 other amino acid substitutions in the above-exemplified combinations of amino acid substitutions.
Examples include combinations containing one or six. Examples of combinations of amino acid substitutions that include other amino acid substitutions include combinations that further include at least the amino acid substitution of Asn62Tyr in the combinations of amino acid substitutions exemplified above.

Examples of proteins of the present invention that further have the above-mentioned other amino acid substitutions include the following proteins. The immunoglobulin adsorbent of the present invention, which is obtained by immobilizing the protein on an insoluble carrier, can absorb immunoglobulins (antibodies) having κ light chains at a mild pH, regardless of the subgroup, in comparison with conventional immunoglobulin adsorbents. This is preferable because it can be eluted under certain conditions.
Contains the amino acid sequence set forth in SEQ ID NO: 1, provided that in the amino acid sequence, Glu4G
ly, Pro6Ser, Lys7Ala, Lys13Arg, Lys22Arg, Ile
23Arg, Lys29Ile, Lys38Glu, Asn44Arg, Lys48Ar
g, Glu49Asp, Asn50Tyr, Tyr53Phe, Asn62Tyr, Ly
Immunoglobulin-binding protein having amino acid substitutions of s67Arg and Ala69Val (immunoglobulin-binding protein comprising the amino acid sequence set forth in SEQ ID NO: 207)
.
Contains the amino acid sequence set forth in SEQ ID NO: 1, provided that in the amino acid sequence, Glu4G
ly, Pro6Ser, Lys7Ala, Lys13Arg, Lys22Arg, Ile
23Arg, Lys29Ile, Lys38Glu, Asn44Arg, Lys48Hi
s, Glu49Asp, Asn50Tyr, Tyr53Phe, Asn62Tyr, Il
An immunoglobulin-binding protein having amino acid substitutions of e64Leu, Lys67Arg and Ala69Val (an immunoglobulin-binding protein comprising the amino acid sequence set forth in SEQ ID NO: 212).

In other words, examples of amino acid substitutions that the protein of the present invention has include the following:
Glu4Gly, Pro6Ser, Lys7Ala, Lys13Arg, Lys22Ar
g, Ile23Arg, Lys29Ile, Lys38Glu, Asn44Arg, Ly
s48Arg, Glu49Asp, Asn50Tyr, Tyr53Phe, Asn62T
Amino acid substitutions of yr, Lys67Arg and Ala69Val;
Glu4Gly, Pro6Ser, Lys7Ala, Lys13Arg, Lys22Ar
g, Ile23Arg, Lys29Ile, Lys38Glu, Asn44Arg, Ly
s48His, Glu49Asp, Asn50Tyr, Tyr53Phe, Asn62T
Amino acid substitutions of yr, Ile64Leu, Lys67Arg and Ala69Val.

In this specification, the above-exemplified amino acid substitutions (
That is, amino acid substitution at the specific position and any Glu49Asp or Pro6S
An amino acid sequence having other amino acid substitutions such as er is also referred to as a "substituted amino acid sequence derived from SEQ ID NO: 1." In other words, the substituted amino acid sequence derived from SEQ ID NO.
This is the amino acid sequence set forth in SEQ ID NO: 1 with other amino acid substitutions such as ro6Ser.
In other words, the substituted amino acid sequence derived from SEQ ID NO: 1 is the amino acid substitution (
That is, amino acid substitution at the specific position and any Glu49Asp or Pro6S
The amino acid sequence is the same as the amino acid sequence set forth in SEQ ID NO: 1, except that it has other amino acid substitutions such as er. The substituted amino acid sequence derived from SEQ ID NO: 1 is an example of a modified amino acid sequence in this specification.

The modified amino acid sequences used herein include variant sequences of the modified amino acid sequences exemplified above (for example, substituted amino acid sequences derived from SEQ ID NO: 1). That is, the protein of the present invention includes a protein that includes a variant sequence of the above-exemplified modified amino acid sequence (eg, substituted amino acid sequence derived from SEQ ID NO: 1) and has immunoglobulin binding activity. Hereinafter, the case of a variant sequence of a substituted amino acid sequence derived from SEQ ID NO: 1 will be explained as an example, but the explanation can be applied mutatis mutandis to a variant sequence of any modified amino acid sequence.

The variant sequence of the substituted amino acid sequence derived from SEQ ID NO: 1 shall be set so that the amino acid substitution at the specific position remains (that is, the protein of the present invention has the amino acid substitution at the specific position). In addition, the variant sequence of the substituted amino acid sequence derived from SEQ ID NO: 1 is set so that other amino acid substitutions such as Glu49Asp and Pro6Ser remain (that is, the protein of the present invention has other amino acid substitutions such as Glu49Asp and Pro6Ser). You can. In addition, variant sequences of the substituted amino acid sequence derived from SEQ ID NO: 1 include, for example, the amino acid substitutions exemplified above (that is, amino acid substitutions at the specific positions and other amino acid substitutions such as arbitrary Glu49Asp and Pro6Ser).
The substituted amino acid sequence derived from SEQ ID NO: 1 may additionally have one or more amino acid substitutions selected from SEQ ID NO: 1-derived substituted amino acid sequence. For example, the substituted amino acid sequence derived from SEQ ID NO: 1 is Glu49As
In the case where there is no other amino acid substitution such as p or Pro6Ser, the variant sequence of the substituted amino acid sequence derived from SEQ ID NO: 1 may have the other amino acid substitution.

Variant sequences of the substituted amino acid sequence derived from SEQ ID NO: 1 include substitutions, deletions, insertions, and/or additions of one or several amino acid residues at one or several positions in the substituted amino acid sequence derived from SEQ ID NO: 1. Examples include amino acid sequences containing. That is, as long as the protein of the present invention has immunoglobulin binding activity, in addition to the amino acid substitutions exemplified above (i.e., the amino acid substitutions at the specific positions and any other amino acid substitutions such as Glu49Asp and Pro6Ser), SEQ ID NO. In the amino acid sequence described in 1
or may contain substitutions, deletions, insertions, and/or additions of one or several amino acid residues at several positions. That is, the protein of the present invention includes the amino acid sequence set forth in SEQ ID NO: 1, but in the amino acid sequence, the amino acid substitutions exemplified above (i.e., the amino acid substitutions at the specific positions and any Glu49Asp or Pro6
other amino acid substitutions, such as Ser), and further contains substitutions, deletions, insertions, and/or additions of one or more amino acid residues at one or more positions, and has no immunoglobulin binding activity. Also included are proteins that have. In other words, the protein of the present invention has, for example, the amino acid substitution exemplified above (i.e., the amino acid substitution at the specific position and any other amino acid substitution such as Glu49Asp or Pro6Ser), and further has one or more amino acid substitutions at one or several positions. Alternatively, it may be a protein that contains the same amino acid sequence as SEQ ID NO: 1 except for the substitution, deletion, insertion, and/or addition of several amino acid residues, and has immunoglobulin binding activity. In addition, substitutions, deletions, insertions, etc. of the above amino acid residues,
and/or the addition shall be selected such that the amino acid substitution at said specific position remains. That is, the above-mentioned substitution, deletion, insertion, and/or addition of amino acid residues may occur, for example, at positions other than the above-mentioned specific positions. Furthermore, the above amino acid residue substitutions, deletions, insertions, and/or additions may be selected such that the other amino acid substitutions remain. That is, the above amino acid residue substitutions, deletions, insertions, and/or additions may occur, for example, at positions other than the other amino acid substitutions. In addition, the substitution, deletion, insertion, and/or addition of the above amino acid residues may be, for example, one or more amino acid substitutions selected from the amino acid substitutions exemplified above that are not present in the substituted amino acid sequence derived from SEQ ID NO: 1. May contain. The above-mentioned "one or several" varies depending on the position of the amino acid residue in the three-dimensional structure of the protein and the type of amino acid residue, but specifically, for example, 1 to 20, 1 to 10, 1 to 10. 9 pieces, 1 to 8 pieces, 1 to 7 pieces, 1 to 6 pieces, 1 to 5 pieces, 1 to 4 pieces,
It means 1 to 3, 1 to 2, or 1. An example of the above amino acid residue substitutions includes conservative substitutions in which amino acids with similar physical and/or chemical properties are substituted. It is known by those skilled in the art that in the case of conservative substitutions, the protein function is generally maintained between the protein in which the substitution has occurred and the protein in which the substitution has not occurred. Examples of conservative substitutions include substitutions between glycine and alanine, serine and proline, or glutamic acid and alanine (Protein Structure and Function, Medical Science International, Inc., 9, 2005). In addition, substitution of the above amino acid residues,
Deletions, insertions, and/or additions may be caused by naturally occurring mutations (mutants or variants), for example, due to individual differences or species differences in the microorganism from which the protein or the gene encoding it is derived. It also includes things that occur.

Variant sequences of the substituted amino acid sequence derived from SEQ ID NO: 1 also include amino acid sequences that have high homology to the substituted amino acid sequence derived from SEQ ID NO: 1. That is, the protein of the present invention includes the amino acid substitutions exemplified above in the amino acid sequence set forth in SEQ ID NO: 1 (i.e., amino acid substitutions at the specific positions and optionally Glu49Asp and P
Also included are proteins that contain an amino acid sequence that has high homology to an amino acid sequence that has other amino acid substitutions such as ro6Ser, and have immunoglobulin binding activity.
Note that changes in the amino acid sequence within the range of homology as described above are selected such that the amino acid substitution at the specific position remains. That is, a change in the amino acid sequence within the range of homology as described above may occur, for example, at a position other than the specific position. Furthermore, changes in the amino acid sequence within the range of homology as described above may be selected such that other amino acid substitutions remain. That is, changes in the amino acid sequence within the range of homology as described above may occur, for example, at positions other than other amino acid substitutions. In addition, changes in the amino acid sequence within the range of homology as described above may be made, for example, in SEQ ID NO: 1 selected from the amino acid substitutions exemplified above.
It may contain one or more amino acid substitutions that the derived substituted amino acid sequence does not have. The term "homology" may mean similarity or identity, and in particular may mean identity. "Homology to an amino acid sequence" means homology to the entire amino acid sequence. The above-mentioned "high homology" may mean a homology of 70% or more, 80% or more, 90% or more, or 95% or more. "Identity" between amino acid sequences refers to the proportion of amino acid residues of the same type in those amino acid sequences (
Experimental Medicine February 2013 Vol. 31 No. 3, Yodosha). between the amino acid sequences.
"Similarity" means the sum of the ratio of amino acid residues that are the same in their amino acid sequences and the ratio of amino acid residues that have similar side chain properties (Jikken Igaku February 2013 issue)
Vol. 31 No. 3, Yodosha). Amino acid residues with similar side chain properties are as described above. Amino acid sequence homology was determined using BLAST (Basic Local Ali
gnment Search Tool) and alignment programs such as FASTA (
alignment program).

In addition, as modified amino acid sequences, in the variant sequences exemplified above, further:
The amino acid substitutions exemplified above (i.e., amino acid substitutions at the specific positions and optionally G
Also included are amino acid sequences having one or more amino acid substitutions selected from lu49Asp and other amino acid substitutions such as Pro6Ser. For example, the modified amino acid sequence may be a variant sequence that has an amino acid substitution at least at the specific position, and an amino acid sequence that also has other amino acid substitutions.

Further, examples of the unmodified amino acid sequence include variant sequences of the unmodified amino acid sequence exemplified above (for example, the amino acid sequence set forth in SEQ ID NO: 1). That is, the modified amino acid sequence includes the above-exemplified amino acid substitution (i.e., the amino acid substitution at the specific position and optionally the Glu49Asp and other amino acid substitutions such as Pro6Ser and Pro6Ser. That is, the protein of the present invention is
Contains a variant sequence of the unmodified amino acid sequence exemplified above (for example, the amino acid sequence set forth in SEQ ID NO: 1), but in the variant sequence, the amino acid substitutions exemplified above (i.e., amino acid substitutions at the specific positions and optionally Glu49Asp or Pro6Ser) are included.
Also included are proteins that have other amino acid substitutions, such as, and have immunoglobulin binding activity. In other words, the protein of the present invention is, for example, a protein containing the same amino acid sequence as a variant sequence of the unmodified amino acid sequence exemplified above (for example, the amino acid sequence set forth in SEQ ID NO: 1) except for having the amino acid substitutions exemplified above. It may be. Note that the variant sequence of the non-modified amino acid sequence exemplified above (for example, the amino acid sequence set forth in SEQ ID NO: 1) may or may not actually exist in a bacterium belonging to the genus Finegoldia. That is, "the amino acid sequence of the immunoglobulin-binding domain of Protein L derived from a bacterium belonging to the genus Finegoldia (the amino acid sequence of the immunoglobulin-binding domain of FpL)"
” is not limited to the amino acid sequence of the immunoglobulin binding domain of Protein L that actually exists in bacteria of the genus Finegoldia, but also a variant sequence of the same amino acid sequence that does not actually exist in bacteria of the genus Finegoldia (i.e., a hypothetical) amino acid sequence. Also includes. Hereinafter, a case of a variant sequence of the amino acid sequence set forth in SEQ ID NO: 1 will be explained as an example, but the explanation can be applied mutatis mutandis to a variant sequence of any non-modified amino acid sequence.

Variant sequences of the amino acid sequence set forth in SEQ ID NO: 1 include substitutions, deletions, and insertions of one or several amino acid residues at one or several positions in the amino acid sequence set forth in SEQ ID NO: 1. or an amino acid sequence containing an addition. That is, the protein of the present invention includes the amino acid sequence set forth in SEQ ID NO: 1, but in the amino acid sequence, substitution, deletion, or insertion of one or several amino acid residues at one or several positions,
and/or addition, and further has the amino acid substitutions exemplified above (that is, amino acid substitutions at the specific positions and optionally other amino acid substitutions such as Glu49Asp and Pro6Ser), and also has immunoglobulin binding activity. The above-mentioned substitutions, deletions, insertions, and/or additions of amino acid residues may occur, for example, at positions other than the above-mentioned specific positions. Furthermore, the above-mentioned substitutions, deletions, insertions, and/or additions of amino acid residues may occur, for example, at positions other than the other amino acid substitutions.

Variant sequences of the amino acid sequence set forth in SEQ ID NO: 1 also include amino acid sequences that have high homology to the amino acid sequence set forth in SEQ ID NO: 1. That is, the protein of the present invention includes an amino acid sequence that has high homology to the amino acid sequence set forth in SEQ ID NO: 1, provided that the protein contains an amino acid sequence that has high homology to the amino acid sequence set forth in SEQ ID NO: 1. Also included are proteins that have the amino acid substitutions exemplified above (that is, amino acid substitutions at the specific positions and optionally other amino acid substitutions such as Glu49Asp and Pro6Ser) in the amino acid sequence) and have immunoglobulin binding activity.
Changes in amino acid residues within the range of homology as described above may occur, for example, at positions other than the specific positions. Furthermore, changes in amino acid residues within the range of homology as described above may occur, for example, at positions other than other amino acid substitutions.

In addition, regarding the variant sequence of the amino acid sequence set forth in SEQ ID NO: 1, the description regarding the variant sequence of the substituted amino acid sequence derived from SEQ ID NO: 1 can be applied mutatis mutandis.

As used herein, "the X-th amino acid in the amino acid sequence set forth in SEQ ID NO: 1" means the amino acid present at position X counting from the N-terminus of the amino acid sequence set forth in SEQ ID NO: 1. In a specific amino acid sequence, "the amino acid residue corresponding to the X-th amino acid in the amino acid sequence set forth in SEQ ID NO: 1" refers to the amino acid residue in the specific amino acid sequence, and the specific amino acid sequence and SEQ ID NO. Alignment with the amino acid sequence of 1 (
It means an amino acid residue arranged at the same position as the X-th amino acid in the amino acid sequence shown in SEQ ID NO: 1 in alignment). For example, in the case of Lys7Gln amino acid substitution, the "amino acid residue corresponding to the 7th lysine of SEQ ID NO: 1" in a specific amino acid sequence is the amino acid residue in the specific amino acid sequence, and the specific amino acid Refers to the amino acid residue arranged at the same position as the 7th lysine in the amino acid sequence shown in SEQ ID NO: 1 in the alignment of the sequence and the amino acid sequence shown in SEQ ID NO: 1.
In addition, in the amino acid sequence set forth in SEQ ID NO: 1, "the amino acid residue corresponding to the X-th amino acid in the amino acid sequence set forth in SEQ ID NO: 1" refers to the X-th amino acid itself in the amino acid sequence set forth in SEQ ID NO: 1. means. That is, the amino acid substitutions exemplified above (
That is, the position of the amino acid substitution at said specific position and optionally other amino acid substitution) is
It does not necessarily indicate an absolute position in the protein of the present invention, but a relative position based on the amino acid sequence set forth in SEQ ID NO: 1. That is, for example, the protein of the present invention may include insertion of an amino acid residue on the N-terminal side of the amino acid substitution position exemplified above,
If deletions or additions are involved, the absolute position of the amino acid substitution may vary accordingly. The position of the amino acid substitution exemplified above in the protein of the present invention can be identified, for example, by alignment of the amino acid sequence of the domain and the amino acid sequence set forth in SEQ ID NO: 1. Alignment can be performed, for example, using an alignment program such as BLAST or FASTA. The same applies to the positions of amino acid substitutions exemplified above in any amino acid sequence such as a variant sequence of the amino acid sequence set forth in SEQ ID NO: 1. In addition, the amino acid substitutions exemplified above (i.e., amino acid substitutions at the specific positions and optionally Glu4
The amino acid residue before substitution (other amino acid substitutions such as 9Asp and Pro6Ser) indicates the type of amino acid residue before substitution in the amino acid sequence set forth in SEQ ID NO: 1, and the amino acid residue before substitution in the amino acid sequence set forth in SEQ ID NO: 1. It may or may not be conserved in other non-modified amino acid sequences.

The protein of the present invention may contain only one modified amino acid sequence, or may contain multiple modified amino acid sequences. The protein of the present invention may contain, for example, 2 or more, 3 or more, 4 or more, or 5 or more modified amino acid sequences, and 10 or less, 7 or more modified amino acid sequences.
The number may be less than or equal to 5, less than or equal to 4, less than or equal to 3, or less than or equal to 2, or may contain any consistent combination thereof. When the protein of the present invention includes multiple modified amino acid sequences, the amino acid sequences of the multiple modified amino acid sequences may or may not be the same. These multiple modified amino acid sequences are directly connected (directly connected)
They may be connected via an appropriate linker (for example, an oligopeptide consisting of 5 or more and 25 or less amino acid residues).

The protein of the present invention may consist of a modified amino acid sequence or may further contain other amino acid sequences. That is, the protein of the present invention may further include other amino acid sequences, for example, on its N-terminal side or C-terminal side. In other words, in the protein of the present invention, for example, on the N-terminal side or C-terminal side of the modified amino acid sequence,
Other amino acid sequences may be added. Other amino acid sequences include oligopeptides. Examples of oligopeptides used as other amino acid sequences include oligopeptides other than the linker described above. Other amino acid sequences are not particularly limited as long as they do not impair the immunoglobulin binding activity or stability of the protein of the present invention. For example, the type and length of other amino acid sequences are not particularly limited as long as they do not impair the immunoglobulin binding properties or stability of the protein of the present invention.

The proteins of the invention may, for example, contain portions of other immunoglobulin binding domains in addition to the selected immunoglobulin binding domain. For example, when the protein of the present invention contains a modified amino acid sequence of domain C3 of FpL, the protein of the present invention further contains a part of the N-terminal region (domain C1, domain C2) of domain C3 of FpL. It may contain a part of the C-terminal region (domain C4) of domain C3 of FpL.

The protein of the present invention may contain, for example, at its N-terminus or C-terminus, an oligopeptide useful for specifically detecting or separating a target substance. Such oligopeptides include polyhistidine and polyarginine. Furthermore, the protein of the present invention may contain, for example, at its N-terminus or C-terminus, an oligopeptide useful when immobilizing the protein of the present invention on a solid phase such as a support for chromatography. . Such oligopeptides include oligopeptides containing lysine and cysteine.

When the protein of the present invention contains another amino acid sequence as described above, the protein of the present invention may be manufactured in advance in a form containing the other amino acid sequence, for example, or may be prepared in a form containing the other amino acid sequence separately manufactured. The amino acid sequence may be added. When the protein of the present invention includes other amino acid sequences as described above, the protein of the present invention typically comprises a polypeptide encoding the full-length amino acid sequence of the protein of the present invention that includes the other amino acid sequences as described above. It can be produced by expressing it from nucleotides. That is, for example, a polynucleotide encoding another amino acid sequence and a polynucleotide encoding the protein of the present invention (e.g., one that does not contain the other amino acid sequence) may be connected to a polynucleotide encoding the protein of the present invention, such that the other amino acid sequence is on the N-terminal side of the protein of the present invention. Alternatively, the protein of the present invention may be expressed by linking so as to be added to the C-terminal side. For example, another chemically synthesized amino acid sequence may be chemically bonded to the N-terminus or C-terminus of the protein of the present invention (for example, one that does not contain other amino acid sequences).

The protein of the present invention can be produced, for example, by expressing it from a polynucleotide encoding the protein of the present invention. In this specification, a polynucleotide encoding the protein of the present invention is also referred to as a "polynucleotide of the present invention." The polynucleotide of the present invention is
Specifically, it may be a polynucleotide comprising a nucleotide sequence encoding the protein of the present invention.

The polynucleotide of the present invention can be obtained, for example, by chemical synthesis, PCR, or other DNA amplification methods. The DNA amplification method can be carried out using, for example, a polynucleotide containing a nucleotide sequence to be amplified, such as a nucleotide sequence encoding a protein of the present invention, as a template. The polynucleotide used as a template is genomic DNA of an organism expressing the protein of the present invention,
Examples include vectors containing the cDNA of the protein of the present invention and the polynucleotide of the present invention.

The nucleotide sequence of the polynucleotide of the present invention can be designed, for example, by conversion from the amino acid sequence of the protein of the present invention. When converting an amino acid sequence into a nucleotide sequence, a standard codon table can be used, but it is preferable to perform the conversion in consideration of the codon usage frequency in the host to be transformed with the polynucleotide of the present invention. As an example, if the host is Esc
In the case of herichia coli, AGA/A for arginine (Arg)
GG/CGG/CGA, ATA for isoleucine (Ile), CTA for leucine (Leu), GGA for glycine (Gly), and CCC for proline (Pro) are used less frequently (so-called rare codons). ), you may convert to avoid those codons. Analysis of codon usage frequency can be performed using public databases (e.g., Kazusa DN
This is also possible by using Codon Usage Database, etc. available on the website of Research Institute A.

The polynucleotide of the present invention may be obtained by obtaining the entire length of the polynucleotide at once, or by ligating polynucleotides consisting of partial sequences of the polynucleotide after obtaining them. The above description of the method for obtaining the polynucleotide of the present invention is not limited to the case where the full-length sequence thereof is obtained all at once, but can also be applied mutatis mutandis to the case where the partial sequence thereof is obtained.

Note that the polynucleotide of the present invention may be designed to be linked to a polynucleotide encoding the amino acid sequence of any polypeptide to encode a fused amino acid sequence.

The protein of the present invention can be used, for example, in a genetically modified host (
It can be produced by culturing the protein (hereinafter also simply referred to as "the genetically modified host of the present invention") and expressing the protein, and then collecting the expressed protein. The genetically modified host of the present invention can be obtained, for example, by transforming a host using the polynucleotide of the present invention. The host is not particularly limited as long as it can express the protein of the present invention by being transformed with the polynucleotide of the present invention. Examples of hosts include animal cells, insect cells, and microorganisms. Among these, animal cells include COS cells and CHO (Chinese Hamste
Examples of insect cells include Sf9 cells and BTI-TN-5B1-4 cells, and examples of microorganisms include yeast and bacteria. Furthermore, as a yeast, Saccharomyces cer
Yeasts of the genus Saccharomyces such as Evisiae, Pichia Pastori
Yeasts of the genus Pichia such as S, yeasts of the genus Schizosaccharomyces such as Schizosaccharomyces pombe, and as bacteria, Escherichia coli (Esche.
Bacteria belonging to the genus Escherichia, such as (richia coli), can be mentioned. Examples of E. coli include JM109 strain and BL21 (DE3) strain. Note that it is preferable to use yeast or E. coli as a host in terms of productivity, and it is more preferable to use E. coli as a host.

In the genetically recombinant host of the present invention, the polynucleotide of the present invention only needs to be maintained so that it can be expressed. Specifically, the polynucleotide of the present invention may be maintained so as to be expressed under the control of a promoter that functions in the host. When the host is E. coli, examples of promoters that function in the host include trp promoter, tac promoter, tr
c promoter, lac promoter, T7 promoter, recA promoter, lp
Examples include the p promoter.

Furthermore, in the genetically modified host of the present invention, the polynucleotide of the present invention is derived from genomic DNA.
It may exist on a vector that autonomously replicates outside. That is, the genetically modified host of the present invention may be produced by transforming a host with an expression vector containing the polynucleotide of the present invention (hereinafter also simply referred to as "the expression vector of the present invention"). The expression vector of the present invention can be obtained, for example, by inserting the polynucleotide of the present invention into an appropriate position of the expression vector. Note that the expression vector is not particularly limited as long as it can stably exist and replicate within the host to be transformed. When the host is E. coli, expression vectors include pET plasmid vector, pUC
Examples include plasmid vectors and pTrc plasmid vectors. Note that the expression vector of the present invention may include a selection marker such as an antibiotic resistance gene. Furthermore, the above-mentioned appropriate position means a position that does not destroy regions related to the replication function, selection marker, and transmissibility of the expression vector. When inserting the polynucleotide of the present invention into the expression vector, it is preferably inserted while linked to a functional polynucleotide such as a promoter necessary for expression.

Furthermore, in the genetically modified host of the present invention, the polynucleotide of the present invention is derived from genomic DNA.
may be introduced above. Introduction of the polynucleotide of the present invention into genomic DNA can be carried out, for example, by
It can be carried out using a gene introduction method using homologous recombination. As a gene introduction method using homologous recombination, Red-driven integration method (Datsenko, K.
．． A. and Wanner, B. L. , Proc. Natl. Acad. Sci. U.S.
A. , 97:6640-6645 (2000)), a method using a vector containing a temperature-sensitive origin of replication, a method using a vector that does not have an origin of replication that functions within the host, a method using a phage. An example is the transduction method.

Transformation of a host using a polynucleotide such as an expression vector of the present invention can be carried out, for example, by a method commonly used by those skilled in the art. For example, if Escherichia coli is selected as a host, transformation may be performed using the competent cell method, heat shock method, electroporation method, or the like.
The genetically modified host of the present invention can be obtained by screening hosts containing the polynucleotide of the present invention by an appropriate method after transformation.

For information on genetic engineering methods such as expression vectors and promoters that can be used in various microorganisms, see, for example, "Basic Microbiology Course 8 Genetic Engineering," Kyoritsu Shuppan, 1987.
It can be obtained using publicly known documents such as .

When the genetically modified host of the present invention contains the expression vector of the present invention, the expression vector of the present invention can be prepared from the genetically modified host of the present invention. For example, a culture obtained by culturing the genetically modified host of the present invention may be subjected to an alkaline extraction method or QIAprep Spin Minipr.
The expression vector of the present invention can be prepared using a commercially available extraction kit such as ep kit (manufactured by QIAGEN).

The protein of the present invention can be expressed by culturing the genetically modified host of the present invention. Furthermore, the protein of the present invention can be produced by culturing the genetically modified host of the present invention to express the protein of the present invention and collecting the expressed protein. That is, this specification describes a method for producing the protein of the present invention, which includes a step of expressing the protein of the present invention by culturing a genetically modified host of the present invention, and a step of recovering the expressed protein. Disclose. The medium composition and culture conditions may be appropriately set depending on various conditions such as the type of host and the characteristics of the protein of the present invention. The medium composition and culture conditions may be set, for example, to conditions that allow the host to proliferate and express the protein of the present invention. As the medium, for example, a medium containing a carbon source, a nitrogen source, an inorganic salt, and other various organic components and inorganic components as appropriate can be used. Specifically, when the host is E. coli, LB (Luria-Bertani) medium supplemented with necessary nutrients (tryptone 1% (w/v), yeast extract 0.5% (w/v), 1% ( w/v) NaC
l) is mentioned as an example of a preferable medium. In addition, in order to selectively propagate the genetically modified host of the present invention depending on whether or not the expression vector of the present invention is introduced, an antibiotic corresponding to the antibiotic resistance gene contained in the expression vector is added to the culture medium. It is preferable to culture it. For example, if the expression vector contains a kanamycin resistance gene, kanamycin may be added to the medium. The same applies when the polynucleotide of the present invention is introduced onto genomic DNA. The medium may also contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystatin, thioglycolate, and dithiothreitol. The medium may also contain a reagent such as glycine that promotes protein secretion from the transformant into the culture medium. For example, if the host is E. coli, add 2% glycine (
w/v) or less. For example, when the host is E. coli, the culture temperature is generally 10°C or higher and 40°C or lower, preferably 20°C or higher and 37°C or lower, and more preferably around 25°C. For example, when the host is E. coli, the pH of the medium is between pH 6.8 and pH 7.4, preferably around pH 7.0. Further, when the protein of the present invention is expressed under the control of an inducible promoter, it is preferable to induce the protein of the present invention so that the protein can be expressed well. For expression induction, for example, an inducer depending on the type of promoter can be used. As an inducer, IPTG (Isopropyl-β-D-thiogalacto
An example of this is pyranoside. When the host is E. coli, for example, the turbidity of the culture solution (6
Expression of the protein of the present invention can be induced by adding an appropriate amount of IPTG when the absorbance (absorbance at 00 nm) is about 0.5 to 1.0 and continuing culturing. The concentration of IPTG to be added is, for example, 0.005mM or more and 1.0mM or less, preferably 0.01mM or more and 0.01mM or more and 0.01mM or more and 1.0mM or less, for example.
It is 5mM or less. Expression induction such as IPTG induction can be performed, for example, under conditions well known in the art.

The protein of the present invention may be isolated and recovered from the culture by a method suitable for its expression form. In addition, in this specification, "culture" means the whole culture solution obtained by culture|cultivation or a part thereof. The part is not particularly limited as long as it contains the protein of the present invention. Examples of the part include cultured cells of the transformant of the present invention and the culture medium after culture (ie, culture supernatant). For example, when the protein of the present invention accumulates in the culture supernatant, the cells may be separated by centrifugation and the protein of the present invention may be recovered from the resulting culture supernatant. In addition, when the protein of the present invention accumulates within cells (including the periplasm), after collecting the cells by centrifugation, add an enzyme treatment agent, a surfactant, etc. to disrupt the cells, and then extract the protein from the disrupted product. The protein of the invention may be recovered. The protein of the present invention can be recovered from the culture supernatant or cell lysate described above by, for example, a known method used for protein separation and purification. Examples of the recovery method include ammonium sulfate fractionation, ion exchange chromatography, hydrophobic chromatography, affinity chromatography, gel filtration chromatography, and isoelectric precipitation.

The protein of the present invention can be used, for example, in the separation or analysis of immunoglobulins (antibodies). When used for the above purpose, for example, in the form of an immunoglobulin adsorbent (hereinafter also simply referred to as "immunoglobulin adsorbent of the present invention") comprising an insoluble carrier and the protein of the present invention immobilized on the insoluble carrier. Can be used. In this specification, "separation of immunoglobulins" is not limited to separation of immunoglobulins from a solution in the presence of contaminants, but also includes separation of immunoglobulins based on structure, property, activity, etc. The insoluble carrier is not particularly limited as long as it is insoluble in an aqueous solution. Examples of insoluble carriers include carriers made from polysaccharides such as agarose, alginate, carrageenan, chitin, cellulose, dextrin, dextran, and starch, as well as polyvinyl alcohol, polymethacrylate, and poly(2).
Examples include carriers made from synthetic polymers such as -hydroxyethyl methacrylate) and polyurethane, and carriers made from ceramics such as silica. Among these, carriers made from polysaccharides and carriers made from synthetic polymers are preferred as insoluble carriers. Examples of the preferable carriers include polymethacrylate gels with introduced hydroxyl groups such as Toyopearl (manufactured by Tosoh Corporation), agarose gels such as Sepharose (manufactured by Cytiva Corporation), and Cellufine (JN
Examples include cellulose gels such as those manufactured by Company C). The shape of the insoluble carrier is not particularly limited. The insoluble carrier may be in a form that can be packed into a column, for example. Insoluble carriers may be, for example, particulate or non-particulate. Insoluble carriers may also be porous or non-porous, for example.

The immunoglobulin (antibody) to be separated or analyzed in the present invention is not particularly limited as long as it has binding properties to the protein of the present invention. Immunoglobulin is specifically κ
It may have a light chain. In addition to the kappa light chain, immunoglobulins may or may not contain other regions such as an Fc region. Immunoglobulins include, for example, single chain Fv (scFv), Fab, F(ab') ₂ , IgA, bispecific T cell induction (BiT
E) It may be something that does not have an Fc region, such as an antibody. The immunoglobulin may be a monoclonal antibody or a polyclonal antibody. The immunoglobulin may be, for example, any of IgG, IgM, IgA, IgD, and IgE. IgG may be, for example, any of IgG1, IgG2, IgG3, and IgG4. The origin of immunoglobulin is not particularly limited. Immunoglobulins may be derived from a single organism or a combination of two or more organisms. Examples of immunoglobulins include chimeric antibodies, humanized antibodies, human antibodies, and variants thereof (eg, amino acid substitution products). In addition, as immunoglobulins, artificially structurally modified antibodies such as bispecific antibodies, fusion antibodies of κ light chain and other proteins, and complexes of κ light chain and drug (ADC), etc. Antibodies can also be given. Note that "immunoglobulin" also includes antibody drugs.

The protein of the present invention may be immobilized on an insoluble carrier by, for example, a covalent bond. As a specific example, the protein of the present invention can be covalently bonded to the insoluble carrier via an active group that the insoluble carrier has, thereby immobilizing the protein on the insoluble carrier. That is, the insoluble carrier may have active groups on its surface. Examples of the active group include N-hydroxysuccinimide (NHS) activated ester group, epoxy group, carboxy group, maleimide group, haloacetyl group, tresyl group, formyl group, and haloacetamide. As the insoluble carrier having an active group, for example, a commercially available insoluble carrier having an active group may be used as is, or an active group may be introduced into the insoluble carrier. Commercially available carriers having active groups include TOYOPEARL AF-Epoxy-650M, TOYOPEARL
AF-Tresyl-650M (both manufactured by Tosoh Corporation), HiTrap NHS-act
activated HP Columns, NHS-activated Sepharos
e 4 Fast Flow, Epoxy-activated Sepharose
6B (all manufactured by Cytiva), SulfoLink Coupling Resi
An example is n (manufactured by Thermo Fisher Scientific).

Examples of methods for introducing active groups onto the surface of the carrier include a method in which one of the compounds having two or more active sites is reacted with a hydroxy group, epoxy group, carboxy group, amino group, etc. present on the surface of the carrier. .

Compounds that introduce epoxy groups into hydroxy groups and amino groups on the surface of the carrier include:
Examples include epichlorohydrin, ethanediol diglycidyl ether, butanediol diglycidyl ether, and hexanediol diglycidyl ether.

In addition, as a compound that introduces a carboxyl group into the epoxy group present on the surface of the carrier, 2-
Examples include mercaptoacetic acid, 3-mercaptopropionic acid, 4-mercaptobutyric acid, 6-mercaptobutyric acid, glycine, 3-aminopropionic acid, 4-aminobutyric acid, and 6-aminohexanoic acid.

Compounds that introduce maleimide groups into hydroxy groups, epoxy groups, carboxy groups, and amino groups present on the surface of the carrier include N-(ε-maleimidocaproic acid) hydrazide, N-
-(ε-maleimidopropionic acid) hydrazide, 4-(4-N-maleimidophenyl)acetic acid hydrazide, 2-aminomaleimide, 3-aminomaleimide, 4-aminomaleimide,
6-aminomaleimide, 1-(4-aminophenyl)maleimide, 1-(3-aminophenyl)maleimide, 4-(maleimido)phenylisocyanate, 2-maleimidoacetic acid,
3-maleimidopropionic acid, 4-maleimidobutyric acid, 6-maleimidohexanoic acid, N-(
α-maleimidoacetoxy)succinimide ester, (m-maleimidobenzoyl)N
-Hydroxysuccinimide ester, succinimidyl-4-(maleimidomethyl)cyclohexane-1-carbonyl-(6-aminohexanoic acid), succinimidyl-4-(
maleimidomethyl)cyclohexane-1-carboxylic acid, (p-maleimidobenzoyl)N
Examples include -hydroxysuccinimide ester and (m-maleimidobenzoyl)N-hydroxysuccinimide ester.

Compounds that introduce haloacetyl groups into hydroxy groups and amino groups present on the surface of the carrier include chloroacetic acid, bromoacetic acid, iodoacetic acid, chloroacetic acid chloride, bromoacetic acid chloride, bromoacetic acid bromide, chloroacetic anhydride, and bromoacetic acid. anhydride, iodoacetic anhydride,
Examples include 2-(iodoacetamido)acetic acid-N-hydroxysuccinimide ester, 3-(bromoacetamido)propionic acid-N-hydroxysuccinimide ester, and 4-(iodoacetyl)aminobenzoic acid-N-hydroxysuccinimide ester.

In addition, a method for introducing active groups onto the carrier surface is to react ω-alkenyl alkane glycidyl ether with hydroxy groups and amino groups present on the carrier surface, and then halogenate the ω-alkenyl moiety with a halogenating agent. An example of this is a method of activating. Examples of the ω-alkenyl alkane glycidyl ether include allyl glycidyl ether, 3-butenyl glycidyl ether, and 4-pentenyl glycidyl ether. Examples of the halogenating agent include N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide.

Furthermore, as a method for introducing active groups onto the surface of the carrier, a method of introducing active groups into carboxy groups present on the surface of the carrier using a condensing agent and an additive can also be exemplified. As a condensing agent, 1
Examples include -ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), dicyclohexylcarbodiamide, and carbonyldiimidazole. As an additive, N-
Examples include hydroxysuccinimide (NHS), 4-nitrophenol, and 1-hydroxybenztriazole.

The protein of the present invention can be immobilized on an insoluble carrier, for example, in a buffer. Buffers include acetate buffer, phosphate buffer, MES (2-Morpholinoethane
esulfonic acid) buffer, HEPES (4-(2-Hydroxyeth)
yl)-1-piperazineethanesulfonic acid) buffer,
Examples include Tris buffer and borate buffer. The reaction temperature during immobilization can be appropriately set depending on various conditions such as the reactivity of the active group and the stability of the protein of the present invention. The reaction temperature during immobilization may be, for example, 5°C or higher and 50°C or lower, preferably 10°C.
The temperature is above 35°C.

The immunoglobulin adsorbent of the present invention can be used for separating immunoglobulins (antibodies) by, for example, forming a column filled with the above-mentioned adsorbent. For example, by adding a solution containing immunoglobulin to a column filled with the immunoglobulin adsorbent of the present invention, the immunoglobulin is adsorbed to the adsorbent, and the immunoglobulin adsorbed to the adsorbent is eluted. can be separated. That is, the present specification describes a step of adding a solution containing an immunoglobulin to a column filled with the immunoglobulin adsorbent of the present invention to adsorb the immunoglobulin to the adsorbent, and a step of adsorbing the immunoglobulin to the adsorbent. Disclosed is a method for separating immunoglobulin contained in the solution, the method comprising the step of elution. A solution containing immunoglobulin can be added to the column using a liquid delivery means such as a pump, for example. Note that the solution containing immunoglobulin may be solvent-substituted in advance using an appropriate buffer before being added to the column. The column may also be equilibrated with a suitable buffer before adding the immunoglobulin-containing solution to the column. It is expected that, for example, immunoglobulins can be separated with higher purity by column equilibration. Buffers used for solvent replacement and equilibration include phosphate buffer, acetate buffer, and MES.
An example is a buffer solution. Such a buffer solution may further contain, for example, 1mM or more and 1000mM
The following inorganic salts such as sodium chloride may be added. The buffer used for solvent replacement and the buffer used for equilibration may or may not be the same. In addition, if components other than immunoglobulin such as contaminants remain in the column after a solution containing immunoglobulin is passed through the column, such components should be removed before eluting the immunoglobulin adsorbed to the immunoglobulin adsorbent. Components may be removed from the column. Components other than immunoglobulins can be removed from the column using, for example, a suitable buffer. Regarding the buffer used for removing components other than immunoglobulin, for example, the description regarding the buffer used for solvent replacement and equilibration can be applied mutatis mutandis.

The immunoglobulin adsorbed to the immunoglobulin adsorbent can be eluted, for example, by weakening the interaction between the immunoglobulin and the ligand (the protein of the present invention). Examples of means for weakening the interaction between immunoglobulin and the ligand (protein of the present invention) include pH change, addition of a counter peptide, temperature increase, and salt concentration change. A particular example of a means for weakening the interaction between immunoglobulin and the ligand (protein of the present invention) is pH change.
That is, the step of eluting the immunoglobulin adsorbed to the adsorbent can be particularly exemplified by the step of eluting the immunoglobulin adsorbed to the adsorbent by changing the pH. An example of the pH change is a decrease in pH. An example of the decrease in pH is a decrease in pH due to a buffer solution. Specifically, the immunoglobulin adsorbed to the immunoglobulin adsorbent can be eluted using, for example, an appropriate elution solution. Examples of the eluate include buffers that are more acidic than the buffers used for solvent replacement and equilibration. Examples of the acidic buffer include citrate buffer, glycine-hydrochloride buffer, and acetate buffer. That is, by using the acidic buffer solution, the pH can be lowered. The pH of the eluate can be set, for example, within a range that does not impair immunoglobulin functions (antigen binding, etc.). In addition, when the immunoglobulin adsorbed to the immunoglobulin adsorbent is eluted by lowering the pH with a buffer solution, when the protein of the present invention is used as a ligand, it is possible to elute the immunoglobulin adsorbed to the immunoglobulin adsorbent by lowering the pH using a buffer solution. Compared to the case where an immunoglobulin-binding protein is used as a ligand, immunoglobulins can be eluted under conditions of higher pH (closer to neutrality). That is, according to the immunoglobulin adsorbent of the present invention, a milder pH condition (i.e., near-neutral condition) is achieved compared to an immunoglobulin adsorbent using an immunoglobulin-binding protein having an unmodified amino acid sequence as a ligand. Immunoglobulins (antibodies) can be eluted with The pH of the eluate is, for example, 2.5 or higher, 2.6 or higher, 2.7 or higher, 2.8 or higher, 2.9 or higher, 2.95 or higher, 3 or higher, 3.05 or higher, 3.1 or higher. , 3.15 or more, or 3.2 or more, and may be 4 or less, 3.5 or less, 3.3 or less, 3.2 or less, 3.1 or less, or 3 or less,
It may be a non-contradictory combination thereof. Specifically, the pH of the eluate is, for example,
2.5 or more and 4 or less, 2.8 or more and 4 or less, 2.95 or more and 4 or less, 3 or more and 4 or less, or 3.
It may be 05 or more and 4 or less.

By separating immunoglobulins (antibodies) using the method described above, separated immunoglobulins can be obtained. That is, in one embodiment, the method for isolating immunoglobulin may be a method for producing immunoglobulin, and specifically, it may be a method for producing isolated immunoglobulin. Immunoglobulin is obtained, for example, as an elution fraction containing immunoglobulin. That is, a fraction containing eluted immunoglobulin can be collected. Fractions may be collected, for example, by a conventional method. Methods for separating fractions include changing the collection container at fixed time intervals or fixed volume intervals, changing the collection container according to the shape of the chromatogram of the eluate, and using an autosampler etc. Examples include a method of separating fractions using an automatic fraction collector or the like. Furthermore, immunoglobulins can also be recovered from fractions containing immunoglobulins. Immunoglobulin can be recovered from the immunoglobulin-containing fraction by, for example, a known method used for protein separation and purification.

Hereinafter, the present invention will be explained in more detail using Examples and Comparative Examples, but the present invention is not limited to these Examples. Note that the reference examples do not constitute the present invention.

Comparative Example 1 Natural Protein L immunoglobulin binding domain C3 (FpL_C
3) Preparation (1) Preparation of FpL_C3 expression vector (1-1) Finegoldia spp. (Fi
Amino acid sequence of the immunoglobulin binding domain C3 (amino acid residues 394th to 463rd of GenBank No. AAA67503 (SEQ ID NO: 39), hereinafter also referred to as "FpL_C3") of Protein L (hereinafter referred to as FpL) derived from S. negoldia magna A polynucleotide (SEQ ID NO: 2) encoding was synthesized. In addition, when synthesizing,
The 5' end contains a recognition sequence for the restriction enzyme NcoI (5'-CCATGG-3'), and the 3' end contains a nucleotide sequence encoding 6 histidine residues (5'-CATCACCACCA).
TCACCAC-3'; SEQ ID NO: 40), a termination codon, and a recognition sequence for the restriction enzyme HindIII (5'-AAGCTT-3'), respectively.

(1-2) After treating the synthetically obtained polynucleotide containing SEQ ID NO: 2 with restriction enzymes NcoI and HindIII, a band of the desired size was confirmed by agarose gel electrophoresis. After cutting out the desired band, use QIAquick Gel Extractio.
The polynucleotide was purified using n kit (manufactured by QIAGEN).

(1-3) The polynucleotide obtained in (1-2) and the restriction enzymes NcoI and HindI
Plasmid pET-26b digested with II was ligated using a DNA Ligation Kit (manufactured by Takara Bio Inc.). E. coli BL21 (DE3) strain was transformed using the ligation product, and LB (Lu
ria-Bertani) plate medium (37°C, 16 hours).

(1-4) Select the transformant (genetically modified E. coli) obtained in (1-3), and
After culturing in LB medium containing g/mL kanamycin, QIAprep Spin Min
FpL_C described in SEQ ID NO: 1 was purified using iprep kit (manufactured by QIAGEN).
A vector capable of expressing 3 (named pET-FpL_C3) was obtained.

(1-5) Of the expression vector pET-FpL_C3 obtained in (1-4), FpL_
Big Dye Terminator Cycle Sequencing based on the chain terminator method for the polynucleotide encoding C3 and its surrounding region
A cycle sequencing reaction was performed using a ready reaction kit (manufactured by Thermo Fisher Scientific), and a fully automatic DNA sequencer ABI P
The nucleotide sequence was analyzed using Rism 3700 DNA analyzer (manufactured by Thermo Fisher Scientific). In addition, during this analysis, SEQ ID NO: 3 (5'-
TAATACGACTCACTATAGGG-3') or SEQ ID NO: 4 (5'-TATG
An oligonucleotide consisting of the sequence described in CTAGTTATTGCTCAG-3') was used as a sequencing primer.

As a result of sequence analysis, expression vector pET-FpL_C3 contains FpL_C3 (SEQ ID NO: 1).
It was confirmed that the polynucleotide (SEQ ID NO: 2) encoding the above was inserted.

(2) Preparation of FpL_C3 (2-1) 2×YT liquid medium containing 50 μg/mL kanamycin (tryptone 1.
6% (w/v), yeast extract 1% (w/v), sodium chloride 0.5% (w/v))
Inoculate 2 mL with the recombinant E. coli containing pET-FpL_C3 prepared in (1),
Preculture was performed (30°C, 16 hours).

(2-2) 200 μL of the culture solution after pre-culture was mixed with 2×
After inoculating 20 mL of YT liquid medium and culturing at 37°C for 1.5 to 2 hours, 0.05M I
PTG (Isopropyl-β-D-thiogalactopyranoside)
4 μL was added to the mixture, and the culture was further incubated with shaking at 20° C. overnight.

(2-3) After the completion of culture, collect the cultured bacteria by centrifugation, and use BugBuster Pr
A protein extract was prepared using Otein Extraction Reagent (manufactured by Merck Millipore). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(2-4) Ni-NTA equilibrated in advance with 0.05M Tris buffer (pH 7.5) containing 0.5M NaCl and 0.02M imidazole (hereinafter referred to as washing buffer B )
The supernatant clarified in (2-3) was added to a column filled with Sepharose 6 Fast Flow (manufactured by Cytiva), and washed with washing buffer B in an amount 10 times the amount of the carrier packed in the column. A fraction corresponding to FpL_C3 was collected by passing 0.05M Tris buffer (pH 7.5) containing .5M NaCl and 0.5M imidazole.

(2-5) Measure the absorbance of the collected fraction with a spectrophotometer, and determine the FpL_ contained in the fraction.
C3 was quantified. SDS-PAGE (SDS-polyacrylamide electrophoresis) was also performed, and it was confirmed that FpL_C3 was purified to a high degree of purity.

Example 1 Preparation of Protein L immunoglobulin binding domain C4 (FpL_C4) amino acid substitution product (1) Preparation of FpL_C4 lysine substitution product (1-1) FpL immunoglobulin binding domain C4 consisting of the amino acid sequence set forth in SEQ ID NO: 5 (Amino acid residues 468th to 537th of GenBank No. AAA67503 (SEQ ID NO: 39), hereinafter also referred to as "FpL_C4") have all lysine residues (specifically, the 7th and 13th residues of SEQ ID NO: 5). , 22nd, 29th, 48th and 67th lysine residues) are replaced with arginine residues (immunoglobulin-binding protein (
A polynucleotide (SEQ ID NO: 7) encoding SEQ ID NO: 6 (hereinafter also referred to as "FpL_C4KR") was synthesized. When synthesizing, a recognition sequence for the restriction enzyme NcoI (5
'-CCATGG-3'), a nucleotide sequence encoding 6 histidine residues at the 3' end (SEQ ID NO: 40), a stop codon and a restriction enzyme HindIII recognition sequence (5'-A
AGCTT-3') were added to each.

(1-2) The polynucleotide synthesized in (1-1) was purified in the same manner as in Comparative Example 1 (1-2).

(1-3) In the same manner as Comparative Example 1 (1-3), after ligating the polynucleotide obtained in (1-2) with plasmid pET-26b that had been previously digested with restriction enzymes NcoI and HindIII, the ligation E. coli BL21 (DE3) strain was transformed using the product and cultured.

(1-4) The transformant obtained in (1-3) was cultured and plasmid purified in the same manner as in Comparative Example 1 (1-4) to obtain an expression vector (named pET-FpL_C4KR). The nucleotide sequence of the expression vector was analyzed in the same manner as in Comparative Example 1 (1-5).

As a result of sequence analysis, it was confirmed that a polynucleotide (SEQ ID NO: 7) encoding FpL_C4KR (SEQ ID NO: 6) was inserted into the expression vector pET-FpL_C4KR.

(1-5) Purified FpL_C4KR was prepared from a transformant containing pET-FpL_C4KR in the same manner as in Comparative Example 1 (2).

(2) Mutation introduction to FpL_C4KR and library construction (2-1) Using pET-FpL_C4KR obtained in (1) as a template, create a library of saturated substitutions for the 7th, 13th, 22nd, and 29th amino acid residues. Created.
The primers used were the 22c-Trick method (Sabrina Kille et al., ACS Syn
Thetic Biology, 2013, 2, 83-92), appropriate mixed bases were placed at the site of mutation introduction, and it was designed to perform inverse PCR centered on the site of mutation introduction (SEQ ID NOS: 8 to 31). These primers were mixed as a set of 6 for each substitution in the composition shown in Tables 1 and 2, and a PCR Primer mixture solution (Forward/Re
Verse primer mix) was prepared.

(2-2) Inverse PC using pET-FpL_C4KR produced in Example 1 as a template
Site-directed mutagenesis was performed using R. Inverse PCR is performed by preparing a reaction solution with the composition shown in Table 3, heat-treating the reaction solution at 98°C for 2 minutes, performing a first step at 95°C for 10 seconds, and then
One cycle of the reaction consisted of a second step of 5 seconds at ℃ and a third step of 6 minutes at 72℃.
The test was carried out by cycling and finally heat-treated at 72° C. for 7 minutes.

(2-3) After purifying the obtained PCR product, the purified product was used to generate E. coli BL21 (DE3
) strain was transformed and cultured in LB plate medium containing 50 μg/mL kanamycin (37
C, for 16 hours), the colonies formed on the plate were used as a saturated substitution library.

Example 2 Screening for FpL_C4KR amino acid substitution product (1) Transformant capable of expressing FpL_C4KR prepared in Example 1 (1) and saturated substitution product library (transformant) prepared in Example 1 (2) was inoculated into 250 μL of 2×YT liquid medium containing 50 μg/mL kanamycin, and cultured with shaking at 37° C. overnight using a 96 deep well plate.

(2) After culturing, 50 μg/mL kanamycin, 0.3% (w/v) glycine, 0.
Subplant 5 μL of the culture solution into 500 μL of 2×YT liquid medium containing 01 mM IPTG, and
Using a 6 deep well plate, the cells were further cultured with shaking at 20°C overnight.

(3) After culturing, equal amounts of the culture supernatant obtained by centrifugation and 1.0 M NaOH were mixed, and alkali treatment was performed at 38° C. for 15 minutes.

(4) The antibody binding activity of the immunoglobulin binding protein after the alkali treatment was measured by the ELISA method shown below, and the antibody binding activity of the immunoglobulin binding protein when the alkali treatment of (3) was performed. The residual activity was calculated by dividing by the antibody binding activity of the immunoglobulin binding protein when the alkali treatment in (3) was not performed.

(4-1) Using Tris-Buffered Saline (TBS), 10 μg/
A human antibody (gamma globulin preparation, manufactured by Chemo and Serum Therapy Research Institute) prepared in mL was dispensed into each well of a 96-well microplate and immobilized (4° C., 16 hours). After fixation, TB
Blocking was performed using skim milk (manufactured by Becton Dickinson) prepared at 2% (w/v) using S.

(4-2) Washing buffer (0.05M Tris buffer (pH 7.5) containing 0.15M NaCl, 0.05% (w/v) Tween 20 (trade name) , hereinafter "Washing buffer A") After washing each well of a 96-well microplate with a 96-well microplate, a solution containing an immunoglobulin-binding protein to evaluate antibody binding activity was added, and the immunoglobulin-binding protein and immobilized gamma globulin were allowed to react (30 ℃, 1 hour).

(4-3) After the reaction was completed , the well was washed with washing buffer A , and 100 μL/well of Anti-6-His Antibody (manufactured by BETHYL LABORATORIES) diluted to 100 ng/mL was added and reacted (30°C, 1 hour). ).

(4-4) After the reaction was completed , the well was washed with washing buffer A , and TMB Peroxidase Substrate (manufactured by KPL) was added at 50 μL/well. Next, the reaction was stopped by adding 50 μL/well of 1M phosphoric acid, and the absorbance at 450 nm was measured using a microplate reader (manufactured by Tecan).

(5) About 500 transformants were evaluated, and FpL_C4KR (SEQ ID NO: 6) was selected from among them.
We selected transformants expressing immunoglobulin-binding proteins with improved alkaline stability compared to .

(6) Cultivate the transformant selected in (5), QIAprep Spin Minip
An expression vector was prepared using a rep kit (manufactured by QIAGEN).

(7) Analyze the nucleotide sequence of the polynucleotide region encoding the immunoglobulin binding protein inserted into the obtained expression vector by the method described in Comparative Example 1 (1-5), and identify the amino acid substitution site. did.

(8) The transformant expressing the immunoglobulin binding protein selected in (5) was cultured in the same manner as in Comparative Example 1 (2-1) to (2-2). A protein extract was prepared and clarified in the same manner as in 3).

(9) The protein extract clarified in (8) was purified by the method described in Comparative Example 1 (2-4), and a fraction corresponding to immunoglobulin-binding proteins was collected.

(10) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

Example 3 Immunoglobulin elution pH evaluation of the protein of the present invention FpL_C3 (SEQ ID NO: 1) produced in Comparative Example 1, FpL_C4K produced in Example 1
The pH at which immunoglobulin bound to R (SEQ ID NO: 6) or the FpL_C4KR amino acid substituted product obtained in Example 2 can be eluted (hereinafter also simply referred to as "elution pH") was measured by the following method.

(1) IgG Sepharose 6, an insoluble carrier with immobilized immunoglobulin
A 50% (w/v) water slurry of Fast Flow (manufactured by Cytiva) was prepared, and 0.5 mL of the slurry was applied to a Tricorn 5/50 column (inner diameter 5 mm x length 50 mm:
(manufactured by Cytiva) and then pumping pure water to the IgG
An ose-packed column was prepared.

(2) The IgG Sepharose packed column prepared in (1) was packed with AKTA AVAN.
It was installed in T25 (manufactured by Cytiva). The column was soaked in 0.1M citrate buffer (pH
6.5) (hereinafter referred to as solution A) and equilibrated with 0.1M citrate buffer (pH 2.2) (hereinafter referred to as solution B).
After washing with solution A, equilibration was carried out again.

(3) Apply 100 μL of each immunoglobulin-binding protein solution prepared to 1 g/L with Solution A to an IgG Sepharose-packed column, and after pumping 5 column volumes of Solution A, the concentration of Solution B from 0% to 0% in 10 minutes. FpL_C3 was eluted with a linear gradient elution of 100%. The obtained chromatogram was analyzed, and the pH at the elution position where the absorbance was highest was defined as the elution pH.

The results are shown in Table 4. In the amino acid sequence set forth in SEQ ID NO: 6, at least Lys(A
rg) 7Gln (This notation indicates that the amino acid residue corresponding to the 7th lysine in SEQ ID NO: 1 (7th lysine in SEQ ID NO: 5) is once substituted with arginine and then further substituted with glutamine; , other amino acid substitutions shall be interpreted similarly), Ly
s(Arg)13Val, Lys(Arg)22Thr, Lys(Arg)29Pro,
Immunoglobulin-binding proteins having one or more amino acid substitutions selected from Lys(Arg)29Val and Lys(Arg)29Ile were eluted compared to native FpL_C3 (SEQ ID NO: 1) and FpL_C4KR (SEQ ID NO: 6). It can be said that the pH is increased, that is, immunoglobulins (antibodies) bound to immunoglobulin-binding proteins can be eluted under milder pH conditions (that is, conditions close to neutrality).

Reference example 1
In the expression vector pET-FpL_C3 prepared in Comparative Example 1, mutations were randomly introduced into the polynucleotide portion (SEQ ID NO: 2) encoding an immunoglobulin-binding protein by error-prone PCR.

(1) Error prone PCR was performed using pET-FpL_C3 prepared in Comparative Example 1 as template DNA. In error prone PCR, after preparing a reaction solution with the composition shown in Table 5, the reaction solution is heat-treated at 95°C for 2 minutes, followed by a first step of 30 seconds at 95°C, a second step of 30 seconds at 50°C, and a second step of 72°C. The reaction was carried out for 30 cycles, each cycle consisting of a third step of 90 seconds, and finally heat-treated at 72° C. for 7 minutes. Error prone PCR
Mutations were successfully introduced into the polynucleotide encoding FpL_C3 (SEQ ID NO: 2), and the average mutation introduction rate was 1.6%.

(2) The obtained PCR product was purified, digested with restriction enzymes NcoI and HindIII, and ligated to expression vector pET-26b, which had been previously digested with restriction enzymes NcoI and HindIII.

(3) After the ligation reaction is completed, E. coli BL21 (DE3) strain is transformed using the reaction solution, cultured in LB plate medium containing 50 μg/mL kanamycin (37°C, 16 hours), and then formed on the plate. The resulting colonies were used as a random mutant library.

Reference example 2
(1) Random mutant library (transformants) prepared in Reference Example 1 or transformants expressing FpL_C3 (SEQ ID NO: 1) prepared in Comparative Example 1 were transferred from Example 2 (1) to (2
) The culture supernatant obtained by centrifugation was subjected to the alkali treatment described in Example 2 (3).

(2) The antibody binding activity of the immunoglobulin-binding protein when treated with alkali was measured by the ELISA method described in Example 2 (4), and the antibody binding activity of the immunoglobulin-binding protein when treated with alkaline was determined by the ELISA method described in Example 2 (4). Residual activity was calculated by dividing the binding activity by the antibody binding activity of the immunoglobulin binding protein without alkali treatment.

(3) Approximately 1,600 transformants were evaluated, and natural type (no amino acid substitution) was selected from among them.
Transformants expressing an immunoglobulin binding protein with improved alkaline stability compared to FpL_C3 (SEQ ID NO: 1) were selected.

(4) Cultivate the selected transformant and apply QIAprep Spin Miniprep.
An expression vector was prepared using a kit (manufactured by QIAGEN).

(5) The nucleotide sequence of the polynucleotide region encoding the immunoglobulin binding protein inserted into the obtained expression vector was analyzed by the method described in Comparative Example 1 (1-5), and amino acid substitution sites were determined. Identified.

(6) Each transformant expressing the immunoglobulin-binding protein selected in (5) was inoculated into 2 mL of 2×YT liquid medium containing 50 μg/mL of kanamycin, and incubated at 37°C.
Preculture was performed by aerobically shaking culture overnight.

(7) 200 μL of the preculture solution was inoculated into 20 mL of 2×YT liquid medium supplemented with 50 μg/mL of kanamycin, and cultured with shaking aerobically at 37° C.

(8) Two hours after the start of the culture, the culture temperature was changed to 20°C, IPTG was added to a final concentration of 0.01mM, and cultured with shaking aerobically at 20°C overnight.

(9) After culturing, collect the bacteria by centrifugation and use BugBuster Protein E.
A protein extract was prepared using xtraction Reagent (manufactured by Merck & Co.).

(10) The antibody binding activity of the immunoglobulin-binding protein in the protein extract prepared in (9) was measured using the ELISA method described in Example 2 (4).

(11) Each protein was diluted with TBS so that the concentration was equal. The diluted solution was divided into two equal parts, 0.2M NaOH (alkali treated) was added to one part, and TBS (not treated with alkali) was added to the other part in equal amounts. After mixing, the mixture was allowed to stand at 25°C for 5 hours.

(12) After adding 4 times the amount of 1M Tris buffer (pH 7.0), alkaline treatment (final concentration 0)
．． The antibody binding activity of the protein solution (treated with 1M NaOH at 25° C. for 5 hours) and untreated with alkali was measured by the ELISA method described in Example 2 (4). The residual activity was calculated by dividing the antibody binding activity of the alkali-treated immunoglobulin binding protein by the antibody binding activity of the immunoglobulin binding protein that was not treated with alkali, and the alkali stability was evaluated.

The results are shown in Table 6. In the amino acid sequence set forth in SEQ ID NO: 1, at least Pro3S
er (this notation indicates that the amino acid residue corresponding to the third proline in SEQ ID NO: 1 is substituted with serine; the same applies hereinafter), Glu5Val, Glu8Gly, Ile17Ph
e, Glu27Gly, Ala41Thr, Asn44Ser, Glu49Val, As
n50Ser, Asn50Tyr, Asn50Lys, Asn50Asp, Glu52V
al, Glu52Gly, Thr54Ile, Asn62Tyr and Asn65Tyr
It can be said that an immunoglobulin-binding protein having one or more amino acid substitutions selected from the above has improved alkaline stability compared to natural FpL_C3 (SEQ ID NO: 1).

Among them, an immunoglobulin-binding protein (SEQ ID NO: 47, named FpL_C3 2a) with amino acid substitutions of Asn50Tyr and Glu52Gly was confirmed to have significantly improved alkaline stability (natural FpL_C3: 40%, FpL_C3 2a: 94%). . G
Since the alkali stability improvement in the immunoglobulin binding protein (SEQ ID NO: 52) having a single amino acid substitution of lu52Gly was not remarkable (natural FpL_C3: 40%,
SEQ ID NO: 51:48%), the amino acid substitution that results in a marked improvement in alkaline stability is Asn
It is estimated that it is 50Tyr.

Reference example 3
(1) Using pET-FpL_C4KR obtained in Example 1 as a template, the 7th and 2nd
A saturated substitution library for the 9th amino acid residue was created. As in Example 1 (2), the primers were designed in accordance with the 22c-Trick method, placing appropriate mixed bases at the mutation introduction site, and allowing inverse PCR to be performed centered on the mutation introduction site (SEQ ID NO: 55). 66). These primers were mixed as a set of six for each substitution in the compositions shown in Tables 1 and 7, and a PCR Primer mixture (Forward/Reverse primer
mer mix) was prepared.

(2) Inverse PCR was performed in the same manner as in Example 1 (2-2) except that pET-FpL_C3 was used as the template DNA.

(3) After purifying the obtained PCR product, E. coli BL21 (DE3) strain was transformed using the reaction solution, and cultured in LB plate medium containing 50 μg/mL kanamycin (37°C, 16
The colonies formed on the plate were used as a site-specific mutant library.

Reference example 4
(1) The transformant expressing FpL_C4KR (SEQ ID NO: 6) prepared in Example 1 and the site-specific amino acid substitution library (transformant) prepared in Reference Example 3 were used in Example 2 (
After culturing in the same manner as in 1) to (2), the culture supernatant obtained by centrifugation was subjected to the alkali treatment described in Example 2 (3).

(2) The antibody binding activity of the immunoglobulin-binding protein when treated with alkali was measured by the ELISA method described in Example 2 (4), and the antibody binding activity of the immunoglobulin-binding protein when treated with alkaline was determined by the ELISA method described in Example 2 (4). Residual activity was calculated by dividing the binding activity by the antibody binding activity of the immunoglobulin binding protein without alkali treatment.

(3) About 200 transformants were evaluated, and FpL_C4KR (SEQ ID NO: 6) was selected from among them.
We selected transformants expressing immunoglobulin-binding proteins with improved alkaline stability compared to .

(4) Cultivate the selected transformant and apply QIAprep Spin Miniprep.
An expression vector was prepared using a kit (manufactured by QIAGEN).

(5) Analyze the nucleotide sequence of the polynucleotide region encoding the immunoglobulin binding protein inserted into the obtained expression vector by the method described in Comparative Example 1 (1-5), and identify the amino acid substitution site. did.

(6) A transformant expressing the immunoglobulin binding protein selected in (3) or a transformant expressing FpL_C4KR (SEQ ID NO: 6) prepared in Reference Example 1 was transferred to Reference Example 2.
The cells were cultured in the same manner as in (6) to (8), and a protein extract was prepared in the same manner as in Reference Example 2 (9).

(7) The antibody binding activity of the immunoglobulin-binding protein in the protein extract prepared in (6) was measured using the ELISA method described in Example 2 (4).

(8) After alkali treatment using the method described in Reference Example 2 (11), residual activity was calculated using the same method as in Reference Example 2 (12) to evaluate alkali stability.

Immunoglobulin binding protein (SEQ ID NO: 6) expressed by the transformant selected in (3)
Table 8 shows the results of amino acid substitution positions and residual activity [%] after alkali treatment. In the amino acid sequence set forth in SEQ ID NO: 6, at least Lys(Arg
) 7Ala (This notation indicates that the amino acid residue corresponding to the 7th lysine in SEQ ID NO: 1 (the 7th lysine in SEQ ID NO: 5) is once substituted with arginine and then further substituted with alanine. The same applies hereinafter. ) and/or Lys(Arg)29Pro amino acid substitutions can be said to have improved alkaline stability compared to FpL_C4KR (SEQ ID NO: 6).

Example 4 Preparation of FpL_C3 amino acid substitution product Lysine residues (specifically, 7th and 1st of SEQ ID NO: 1) of FpL_C3 (SEQ ID NO: 1)
3rd, 22nd, 29th, 38th, 48th and 67th lysine residue),
7th lysine residue to alanine residue,
13th, 38th, 48th and 67th lysine residues to arginine residues,
22nd lysine residue to glutamine residue,
29th lysine residue to isoleucine residue,
Each substituted immunoglobulin binding protein (SEQ ID NO: 69, hereinafter “FpL_C3
Amino acid substitutions that were revealed in Reference Example 2 and are involved in improving the alkaline stability of immunoglobulin-binding proteins were collected. Specifically, the immunoglobulin-binding protein shown below was designed and produced.
Asn50Tyr, Glu52Gly and Asn62Tyr for FpL_C3KX
Protein with amino acid substitution introduced (named FpL_C3KX 3a)

(1) The nucleotide sequence of the expression vector pET-FpL_C3KX 3a containing a polynucleotide (SEQ ID NO: 71) encoding pET26b and FpL_C3KX 3a (SEQ ID NO: 70) was designed and divided into the following three regions.

First region: nucleotide sequence of pET26b, 1st to 20th of FpL_C3KX 3a
The nucleotide sequence encoding the amino acid residues up to 60th (from 1st to 60th of SEQ ID NO: 71)
Nucleotide sequence encoding amino acid residues 53 to 70 of FpL_C3KX 3a (nucleotide sequence 157 to 210 of SEQ ID NO: 71), nucleotide sequence encoding 6 histidine residues (SEQ ID NO: 40), termination codon and restriction enzyme HindIII recognition sequence (5'-TAAGCTT-
3')

Second region: Nucleotide sequence encoding amino acid residues 16 to 37 of FpL_C3KX 3a (SEQ ID NO: 72 [forward] and 73 [reverse]
polynucleotide consisting of the sequence described in )

Third region: nucleotide sequence encoding amino acid residues 33rd to 57th of FpL_C3KX 3a (SEQ ID NO: 74 [forward] and 75 [reverse]
polynucleotide consisting of the sequence described in )

(2) A polynucleotide of the first region was prepared by inverse PCR. Inverse PCR uses FpL_C4KR K7A (Lys
Expression vector pET-F containing a polynucleotide (SEQ ID NO: 76) encoding an immunoglobulin binding protein (SEQ ID NO: 67) into which the amino acid substitution of (Arg)7Ala has been introduced
pL_C4KR K7A as PCR Forward Primer with SEQ ID NO: 77
After preparing a reaction solution having the composition shown in Table 9 using the oligonucleotide consisting of the sequence set forth in SEQ ID NO: 78 as a PCR Reverse Primer, the reaction solution was heat-treated at 98° C. for 2 minutes. , a first step of 10 seconds at 95°C, a second step of 50°C for 5 seconds, and a third step of 6 minutes at 72°C are performed for 30 cycles, and finally heat treatment is performed at 72°C for 7 minutes. That's what I did.

(3) The polynucleotide of the first region prepared in (2) and the polynucleotide of the second region and the third region designed in (1) (produced by direct chemical synthesis) were added to NEBu.
ilder (manufactured by New England Biolab). In addition, each of the polynucleotides of the three regions (5 types of polynucleotides) is present in the reaction solution at 0.
．． 05 pmol each were mixed.

(4) The polynucleotide obtained in (2) was purified in the same manner as in Comparative Example 1 (1-2), and transformed in the same manner as in Comparative Example 1 (1-3). Culture and extraction of the expression vector were performed in the same manner as in 1-4), and the nucleotide sequence of the expression vector was analyzed in the same manner as in Comparative Example 1 (1-5).

As a result of sequence analysis, FpL_C3KX was found in the expression vector pET-FpL_C3KX 3a.
It was confirmed that the polynucleotide (SEQ ID NO: 71) encoding 3a (SEQ ID NO: 70) was inserted.

Example 5 Alkaline stability evaluation of FpL_C3KX 3a (1) Natural type FpL_C3 (SEQ ID NO: 1) produced in Comparative Example 1, and mutant immunoglobulin binding proteins FpL_C3KX (SEQ ID NO: 69) and FpL_C3KX produced in Example 4 3a (SEQ ID NO: 70) was transformed into Comparative Example 1
The cells were cultured in the same manner as in (2-1) and (2-2), and a protein extract was prepared in the manner described in Comparative Example 1 (2-3).

(2) The antibody binding activity of the immunoglobulin-binding protein in the protein extract prepared in (1) was measured using the ELISA method described in Example 2 (4).

(3) The concentration of NaOH used in the treatment was 0.4M (final concentration 0.2M), and the treatment time was 15
After the alkali treatment in the same manner as in Reference Example 2 (11), except that the time was changed, Reference Example 2
The residual activity was calculated in the same manner as in (12), and the alkali stability was evaluated.

The results are shown in Table 10. Immunoglobulin binding protein (FpL_C3KX 3a) with amino acid substitutions of Asn50Tyr, Glu52Gly and Asn62Tyr is
It can be said that the alkali stability is improved compared to FpL_C3KX (FpL_C3KX
:10%, FpL_C3KX 3a:69%).

Example 6 Mutation introduction into FpL_C3KX 3a amino acid substitution product and library construction
Mutant immunoglobulin binding protein FpL with amino acid substitution of u49Asp introduced
Vector pET-FpL_C3KX 4h expressing _C3KX 4h (SEQ ID NO: 79)
Among them, mutations were randomly introduced into the polynucleotide portion (SEQ ID NO: 80) encoding an immunoglobulin-binding protein by error-prone PCR in the same manner as in Reference Example 1 to prepare a library. The average mutation introduction rate was 1.7%.

Example 7 Screening for FpL_C3KX 4h amino acid substitution product (1) The random mutant library (transformant) prepared in Example 6 was screened in Example 2 (1
) to (2), and the culture supernatant obtained by centrifugation was diluted with 1.0 M N
It was mixed with aOH in equal amounts and subjected to alkali treatment at 42° C. for 30 minutes.

(2) The antibody binding activity of the immunoglobulin-binding protein when treated with alkali was measured by the ELISA method described in Example 2 (4), and the antibody binding activity of the immunoglobulin-binding protein when treated with alkaline was determined by the ELISA method described in Example 2 (4). Residual activity was calculated by dividing the binding activity by the antibody binding activity of the immunoglobulin binding protein without alkali treatment.

(3) Approximately 900 transformants were evaluated, and transformation was performed to express an immunoglobulin binding protein with improved alkaline stability compared to the alkaline stability improved immunoglobulin binding protein (FpL_C3KX 4h). I chose my body.

(4) Cultivate the selected transformant and apply QIAprep Spin Miniprep.
An expression vector was prepared using a kit (manufactured by QIAGEN).

(5) Analyze the nucleotide sequence of the polynucleotide region encoding the immunoglobulin-binding protein inserted into the obtained expression vector by the method described in Comparative Example 1 (1-5), and identify the amino acid mutation locations. Identified.

(6) A transformant expressing FpL_C3KX 4h (SEQ ID NO: 79) or the immunoglobulin binding protein selected in (5) was cultured in the same manner as in Comparative Example 1 (2-1) to (2-2). A protein extract was prepared in the same manner as in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(7) Ni-NTA Sepharose 6 Fast Flow (manufactured by Cytiva) equilibrated in advance with 0.05M Tris buffer (pH 7.5) ( washing buffer B) containing 0.5M NaCl and 0.02M imidazole. The supernatant clarified in step (6) was added to the column filled with the above column, and after washing with washing buffer B in an amount 10 times the amount of the carrier packed in the column, 0.5M NaCl and 0.5M imidazole were added. A fraction corresponding to immunoglobulin-binding protein was collected by passing 0.05M Tris buffer (pH 7.5) containing the solution.

(8) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding proteins contained in the fractions were quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(9) The concentration of NaOH used in the treatment was 1.0M (final concentration 0.5M), and the treatment time was 15
After the alkali treatment in the same manner as in Reference Example 2 (11), except that the time was changed, Reference Example 2
The residual activity was calculated in the same manner as in (12), and the alkali stability was evaluated.

The results are shown in Table 11. In the amino acid sequence set forth in SEQ ID NO: 79, at least Glu
The immunoglobulin binding protein having one or more amino acid substitutions selected from 9Val, Tyr53Phe, Thr54Met and Ala69Thr is a native FpL_C
FpL_C3KX 4h (SEQ ID NO: 79) has improved alkali stability than 3 (SEQ ID NO: 1).
), it can be said that the alkali stability is improved.

In addition, when we compared the purification yield when cultured in 20 mL medium, we found that Lys(Gln)2
It was confirmed that the protein purification yield was significantly improved by introducing the 2Arg amino acid substitution. Hereinafter, an immunoglobulin-binding protein in which Lys(Gln)22Arg amino acid substitution was introduced into FpL_C3KX 4h was designated as FpL_C3KX 4i (SEQ ID NO: 82).
Name it.

Example 8 Preparation of FpL_C3KX 4i amino acid substitution assembly (1) Design of FpL_C3KX 4i amino acid substitution assembly By integrating with SEQ ID NO: 82), we aimed to further improve stability. Specifically, the immunoglobulin-binding protein shown below was designed and produced.
Protein with Tyr53Phe amino acid substitution introduced into FpL_C3KX 4i (SEQ ID NO: 86, named FpL_C3KX 5e)

(1) A polynucleotide containing a nucleotide sequence encoding FpL_C3KX 5e (SEQ ID NO: 86) was produced by introducing mutations using inverse PCR. Inverse PCR is performed using an expression vector (hereinafter referred to as "pET-FpL_C3KX 4
A method similar to Example 4 (2) except that the oligonucleotide set forth in SEQ ID NO: 88 was used as the PCR Forward Primer, and the oligonucleotide set forth in SEQ ID NO: 89 was used as the PCR Reverse Primer. I did it.

(2) The obtained polynucleotide was purified and treated with the restriction enzyme DpnI, and then the E. coli BL21 (DE3) strain was transformed using the restriction enzyme product.

(3) The obtained transformant was cultured in the same manner as in Reference Example 2 (4), and the expression vector (
pET-FpL_C3KX 5e) was extracted, and the nucleotide sequence of the expression vector was analyzed in the same manner as in Comparative Example 1 (1-5).

As a result of sequence analysis, FpL_C3KX was added to the expression vector pET-FpL_C3KX 5e.
It was confirmed that the polynucleotide encoding 5e (SEQ ID NO: 86) was inserted.

Example 9 Alkaline stability evaluation of FpL_C3KX 4h amino acid substitution product (1) FpL_C3KX 4h (SEQ ID NO: 79), FpL_C3K produced in Example 7
Transformants expressing either X 4i (SEQ ID NO: 82) or FpL_C3KX 5e (SEQ ID NO: 89) produced in Example 8 were treated in the same manner as in Comparative Examples 1 (2-1) to (2-2). A protein extract was prepared in the same manner as in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(2) The supernatant clarified in (1) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(3) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(4) The concentration of NaOH used in the treatment was 1.0M (final concentration 0.5M), and the treatment temperature was 55%.
After alkali treatment in the same manner as in Reference Example 2 (11), except that the temperature and treatment time were 15 minutes, residual activity was calculated in the same manner as in Reference Example 2 (12), and alkali stability was determined. evaluated.

The results are shown in Table 12. FpL_C3KX 5e (SEQ ID NO: 86) produced in Example 8 is FpL_C3KX with improved alkali stability than the natural type FpL_C3 (SEQ ID NO: 1).
4h (SEQ ID NO: 79) and FpL_C3KX 4i (SEQ ID NO: 82), it can be said that the alkali stability is improved (FpL_C3KX 4h: 34%, FpL_C3
KX 4i: 48%, FpL_C3KX 5e: 73%).

Example 10 Mutation introduction into FpL_C3KX 5e and library construction Of the expression vector pET-FpL_C3KX 5e produced in Example 8, Reference Example 1 was added to the polynucleotide portion (SEQ ID NO: 90) encoding an immunoglobulin binding protein.
Mutations were randomly introduced by error-prone PCR in the same manner as above to create a library. The average mutation introduction rate was 1.9%.

Example 11 Screening for FpL_C3KX 5e amino acid substitution product (1) The random mutant library (transformant) prepared in Example 10 was screened in Example 2 (1
) to (2), the culture supernatant obtained by centrifugation was added to Example 7 (
The alkali treatment described in 1) was performed.

(2) The antibody binding activity of the immunoglobulin-binding protein when treated with alkali was measured by the ELISA method described in Example 2 (4), and the antibody binding activity of the immunoglobulin-binding protein when treated with alkaline was determined by the ELISA method described in Example 2 (4). Residual activity was calculated by dividing the binding activity by the antibody binding activity of the immunoglobulin binding protein without alkali treatment.

(3) Approximately 900 transformants were evaluated, and transformation was performed to express an immunoglobulin binding protein with improved alkaline stability compared to the alkaline stability improved immunoglobulin binding protein (FpL_C3KX 5e). I chose my body.

(4) Cultivate the selected transformant and apply QIAprep Spin Miniprep.
An expression vector was prepared using a kit (manufactured by QIAGEN).

(5) Analyze the nucleotide sequence of the polynucleotide region encoding the immunoglobulin binding protein inserted into the obtained expression vector by the method described in Comparative Example 1 (1-5), and identify the amino acid mutation locations. Identified.

(6) A transformant expressing the immunoglobulin binding protein selected in (3) or a transformant expressing FpL_C3KX 5e (SEQ ID NO: 86) prepared in Example 24 was transformed into Comparative Example 1 (2-1). The cells were cultured in the same manner as in (2-2), and a protein extract was prepared in the same manner as in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(7) The supernatant clarified in (6) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(8) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding proteins contained in the fractions were quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(9) The concentration of NaOH used in the treatment was 2.0M (final concentration 1.0M), and the treatment time was 17
After the alkali treatment in the same manner as in Reference Example 2 (11), except that the time was changed, Reference Example 2
The residual activity was calculated in the same manner as in (12), and the alkali stability was evaluated.

The results are shown in Table 13. In the amino acid sequence set forth in SEQ ID NO: 86, at least Glu
An immunoglobulin-binding protein having one or more amino acid substitutions selected from 1Val, Glu4Gly, Gly21Arg and Glu(Gly)52Asp is a native F
It can be said that the alkali stability is improved even when compared with FpL_C3KX 5e (SEQ ID NO: 86), which has improved alkali stability than pL_C3 (SEQ ID NO: 1).

Example 12 Preparation of FpL_C3KX 5e amino acid substitution aggregate (Part 2)
Pro6, which is an amino acid substitution that is involved in improving the alkaline stability of immunoglobulin-binding proteins as revealed in Example 10, and an amino acid substitution that imparts binding strength to Vκ3
Ser and Lys(Arg)38Glu were integrated to FpL_C3KX 5e. Specifically, the immunoglobulin-binding protein shown below was designed and created.
Glu4Gly, Pro6Ser, Lys(Arg)3 for FpL_C3KX 5e
8Glu, protein introduced with amino acid substitution of Glu(Gly)52Asp (SEQ ID NO: 96, named FpL_C3KX 7d)

(1) A polynucleotide (SEQ ID NO: 97) encoding FpL_C3KX 7d (SEQ ID NO: 96) was synthesized. When synthesizing, a recognition sequence for the restriction enzyme NcoI (5'-CCATGG-3') is placed on the 5' end, and a nucleotide sequence encoding 6 histidine residues (SEQ ID NO: 40) is placed on the 3' end. Stop codon and restriction enzyme HindIII recognition sequence (5
'-AAGCTT-3') are added respectively.

(2) The polynucleotide synthesized in (1) was purified in the same manner as in Comparative Example 1 (1-2).

(3) Using the same method as Comparative Example 1 (1-3), ligate the polynucleotide obtained in (2) with plasmid pET-26b that has been previously digested with restriction enzymes NcoI and HindIII, and then use the ligation product to Escherichia coli BL21 (DE3) strain was transformed and cultured.

(4) The obtained transformant was cultured and plasmid purified in the same manner as in Comparative Example 1 (1-4) to obtain an expression vector (named pET-FpL_C3KX8a), and the nucleotide sequence of the expression vector was The analysis was conducted in the same manner as in Comparative Example 1 (1-5).

As a result of sequence analysis, FpL_C3KX was added to the expression vector pET-FpL_C3KX 7d.
It was confirmed that the polynucleotide (SEQ ID NO: 97) encoding 7d (SEQ ID NO: 96) was inserted.

Example 13 Alkali stability evaluation of FpL_C3KX 7d (1) FpL_C3KX 5e (SEQ ID NO: 86) obtained in Example 10 and Example 1
A transformant expressing either FpL_C3KX 7d (SEQ ID NO: 96) obtained in Comparative Example 1 (2-2) was cultured in the same manner as in Comparative Example 1 (2-1) to (2-2). A protein extract was prepared by the method described in -3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(2) The supernatant clarified in (1) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(3) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(4) The concentration of NaOH used in the treatment was 1.0M (final concentration 0.5M), and the treatment time was 17
After the alkali treatment in the same manner as in Reference Example 2 (11), except that the time was changed, Reference Example 2
The residual activity was calculated in the same manner as in (12), and the alkali stability was evaluated.

The results are shown in Table 14. FpL_C3KX8a (SEQ ID NO: 96) evaluated in this example,
It was confirmed that the residual activity was higher than that of FpL_C3KX 5e (SEQ ID NO: 86), and the alkaline stability of these mutant immunoglobulin binding proteins was improved.

Example 14 Mutation introduction into FpL_C3KX 7d and library construction (Part 1)
Vector p expressing FpL_C3KX 7d (SEQ ID NO: 96) produced in Example 12
ET-FpL_C3KX 7d, the polynucleotide portion (SEQ ID NO: 97) encoding an immunoglobulin binding protein was subjected to error-prone PCR in the same manner as in Reference Example 1.
A library was created by randomly introducing mutations. The average mutation introduction rate was 1.9%.

Example 15 Screening for FpL_C3KX 7d amino acid substitution product (Part 1)
(1) The pET-FpL_C3KX 7d (transformant) prepared in Example 12 and the random mutant library (transformant) prepared in Example 13 were transferred from Example 2 (1) to (2).
It was cultured in the same manner.

(2) After culturing, the culture supernatant obtained by centrifugation was mixed with an equal volume of 1.0 M NaOH and treated with alkali at 58° C. for 30 minutes.

(3) The antibody binding activity of the immunoglobulin-binding protein when treated with alkali was measured by the ELISA method described in Example 2 (4), and the antibody binding activity of the immunoglobulin-binding protein when treated with alkali was determined by the ELISA method described in Example 2 (4). Residual activity was calculated by dividing the binding activity by the antibody binding activity of the immunoglobulin binding protein without alkali treatment.

(4) Approximately 1000 transformants were evaluated, and transformants expressing an immunoglobulin-binding protein with improved alkaline stability compared to FpL_C3KX 7d (SEQ ID NO: 96) were selected from among them.

(5) Cultivate the selected transformants and apply QIAprep Spin Miniprep.
An expression vector was prepared using a kit (manufactured by QIAGEN).

(6) The nucleotide sequence of the polynucleotide region encoding the immunoglobulin binding protein inserted into the obtained expression vector was analyzed by the method described in Comparative Example 1 (1-5), and amino acid mutation locations were determined. Identified.

(7) Comparative Example 1 (1- Comparative Example 1 (2-3) was cultured in the same manner as 1) to (1-2).
) A protein extract was prepared in a similar manner. The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(8) The supernatant clarified in (7) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(9) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(10) The concentration of NaOH used in the treatment was 1.0M (final concentration 0.5M), and the treatment time was 1.
After the alkali treatment was performed in the same manner as in Reference Example 2 (11), the residual activity was calculated in the same manner as in Reference Example 2 (12), and the alkali stability was evaluated.

The results are shown in Table 15. In the amino acid sequence set forth in SEQ ID NO: 96, at least Glu
The immunoglobulin-binding protein having one or more amino acid substitutions selected from 8Val, Glu33Val and Ala69Val was compared with FpL_C3KX 7d (SEQ ID NO: 96), which has improved alkaline stability than the natural FpL_C3 (SEQ ID NO: 1). However, it can be said that the alkali stability is improved.

Example 16 Mutation introduction into FpL_C3KX 7d and library construction (Part 2)
(1) Using the vector pET-FpL_C3KX 7d expressing FpL_C3KX 7d (SEQ ID NO: 96) prepared in Example 12 as a template, a library of saturated substitution products for the 23rd, 41st, and 52nd amino acid residues was prepared. The primer is Example 1 (2)
Similarly, following the 22c-Trick method, an appropriate mixed base was placed at the mutation introduction site, and it was designed to perform inverse PCR centered on the mutation introduction site (SEQ ID NO: 100 to 10).
5, 107 to 112, and 115 to 120). These primers were mixed in sets of six for each substitution in the compositions shown in Tables 1 and 16 to prepare a PCR primer mixture (Forward/Reverse primer mix).

(2) Example 2 (2-2) except that pET-FpL_C3KX 7d was used as the template DNA
Site-directed mutagenesis was performed by inverse PCR in the same manner as described above.

(3) After purifying the obtained PCR product, E. coli BL21 (DE3) strain was transformed using the reaction solution, and cultured in LB plate medium containing 50 μg/mL kanamycin (37°C, 16
The colonies formed on the plate were used as a site-specific mutant library.

Example 17 Screening for FpL_C3KX8a amino acid substitution products (Part 2)
(1) A site-specific amino acid substitution library (transformant) prepared using the pET-FpL_C3KX 7d (transformant) prepared in Example 12 and the random mutant library (transformant) prepared in Example 16. After culturing in the same manner as in Examples 2 (1) to (2), the culture supernatant obtained by centrifugation was subjected to the alkali treatment described in Example 15 (2).

(2) The antibody binding activity of the immunoglobulin-binding protein when treated with alkali was measured by the ELISA method described in Example 2 (4), and the antibody binding activity of the immunoglobulin-binding protein when treated with alkali was Residual activity was calculated by dividing the binding activity by the antibody binding activity of the immunoglobulin binding protein without alkali treatment.

(3) Approximately 300 transformants were evaluated, and transformants expressing an immunoglobulin-binding protein with improved alkaline stability compared to FpL_C3KX 7d (SEQ ID NO: 96) were selected from among them.

(4) Cultivate the selected transformant and apply QIAprep Spin Miniprep.
An expression vector was prepared using a kit (manufactured by QIAGEN).

(5) Analyze the nucleotide sequence of the polynucleotide region encoding the immunoglobulin-binding protein inserted into the obtained expression vector by the method described in Comparative Example 1 (1-5), and identify the amino acid mutation locations. Identified.

(6) A transformant expressing the immunoglobulin binding protein selected in (3) or a transformant expressing FpL_C3KX 7d (SEQ ID NO: 96) prepared in Example 12 was transformed into Comparative Example 1 (2-1). The cells were cultured in the same manner as in (2-2), and a protein extract was prepared in the same manner as in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(7) The supernatant clarified in (6) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(8) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding proteins contained in the fractions were quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(9) The concentration of NaOH used in the treatment was 1.0M (final concentration 0.5M), and the treatment time was 15
After the alkali treatment in the same manner as in Reference Example 2 (11), except that the time was changed, Reference Example 2
The residual activity was calculated in the same manner as in (12), and the alkali stability was evaluated.

The results are shown in Table 17. In the amino acid sequence set forth in SEQ ID NO: 96, at least Ile
23Arg, Ala41Ile, Ala41Tyr, Glu(Gly, Asp)52Le
u (this notation indicates that the amino acid residue corresponding to the 7th glutamic acid in SEQ ID NO: 1 was first substituted with glycine, then substituted with aspartic acid, and then substituted with leucine; the same applies hereinafter) and Glu (Gly, Asp) The immunoglobulin-binding protein with the 52Val amino acid substitution is FpL_C3, which has improved alkaline stability than the natural type FpL_C3.
It can be said that the alkali stability is improved compared to KX 7d (SEQ ID NO: 96).

Example 18 Design and production of FpL_C3KX 7d amino acid substitution product A method of introducing substitutions with amino acid residues with different side chain properties or substitutions with amino acid residues of other domains at positions where the amino acid sequence differs between domains. The obtained amino acid substitutions with improved acid elution properties, Pro(Ser)6Ala, Glu8Gly, Glu8
Arg, Gly21Arg, Ile23Phe, Ile23Leu, Glu33Val,
Lys(Arg, Glu)38His, Lys(Arg, Glu)38Leu, Asn4
4His, Asn44Arg, Lys(Arg)48His, Asn(Tyr)50Me
t, Glu(Gly, Asp)52Tyr, Tyr(Phe)53Ser as F
It was accumulated against pL_C3KX 7d.

(1) Expression vector pET-FpL_C3KX 7d containing a polynucleotide (SEQ ID NO: 97) encoding FpL_C3KX 7d (SEQ ID NO: 96) as template DNA
Inverse PCR was performed in the same manner as in Example 4 (2), except that the combinations of oligonucleotides having the sequences listed in the SEQ ID NOs in Table 18 were used as the combinations of CR Forward Primer and PCR Reverse Primer.

(2) The polynucleotide obtained in (1) was purified and treated with the restriction enzyme DpnI, and the product was used to transform Escherichia coli BL21 (DE3) strain.

(3) The obtained transformant was cultured and the expression vector was extracted in the same manner as in Comparative Example 1 (1-4), and the nucleotide sequence of the expression vector was analyzed as in Comparative Example 1 (1-5). It was done in the same way. As a result, it was confirmed that the polynucleotide obtained in (1) was inserted into all expression vectors.

Example 19 Acid dissolution evaluation of FpL_C3KX 7d amino acid substituted product (1) Transformants expressing either FpL_C3KX 7d or the FpL_C3KX 7d amino acid substituted product prepared in Example 18 (15 types in total) were transformed into Comparative Example 1 ( The cells were cultured in the same manner as in 2-1) to (2-2), and a protein extract was prepared in the manner described in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(2) The supernatant clarified in (1) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(3) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(4) Each protein was diluted with TBS so that the concentration was equal. The diluted solution was divided into two equal parts, and one part was treated with 0.0
Antibody binding activity was measured when 5M sodium citrate buffer (pH 3.0) (acid-treated) was added to one side, and TBS (unacid-treated) was added to the other. Residual activity was calculated by dividing the antibody binding activity of the acid-treated immunoglobulin binding protein by the antibody binding activity of the acid-untreated immunoglobulin binding protein. The elution rate was calculated by subtracting the residual activity from 1, and the acid elution property was evaluated.

The results are shown in Table 19. All of the FpL_C3KX 7d amino acid substitution products evaluated in this example had higher elution rates than FpL_C3KX 7d (SEQ ID NO: 96), which has improved alkali stability than the natural FpL_C3 (SEQ ID NO: 1). It was confirmed that the acid elution properties of these mutant immunoglobulin-binding proteins were improved.

Example 20 Preparation of FpL_C3KX 7d amino acid substitution assembly (1) Design of FpL_C3KX 7d amino acid substitution assembly By accumulating on 7d (SEQ ID NO: 96), we aimed to further improve the alkali stability. Specifically, from <a> to <
Two types of immunoglobulin-binding proteins shown in b> were designed and produced.
(ac) FpL_C3KX 7d, Glu(Gly, Asp)52Val and A
Protein with la69Val amino acid substitution introduced (SEQ ID NO: 171, FpL_C3K
(named X 8a)
(b) Glu(Gly,Asp)52Leu and Al for FpL_C3KX 7d
Protein with a69Val amino acid substitution introduced (SEQ ID NO: 174, FpL_C3KX
(named 8b)

(2) Preparation of FpL_C3KX 7d amino acid substitution aggregate Hereinafter, methods for producing the two types of immunoglobulin-binding proteins shown in <a> to <b> above will be described.

<a>FpL_C3KX 8a
<a-1> A polynucleotide containing a nucleotide sequence encoding FpL_C3KX 8a (SEQ ID NO: 271) was produced by introducing mutations using inverse PCR. Inverse PCR uses FpL_C3KX 7d_A69V (FpL_C3KX
an immunoglobulin-binding protein in which an amino acid substitution of Ala69Val is introduced into 7d;
An expression vector (SEQ ID NO: 98) containing a polynucleotide (SEQ ID NO: 168) encoding
Hereinafter, also referred to as “pET-FpL_C3KX 7d_A69V”), PCR Forw
PCR R
The same method as in Example 4(2) was performed except that the oligonucleotide shown in SEQ ID NO: 170 was used as the everse primer.

<a-2> The obtained polynucleotide was purified and treated with the restriction enzyme DpnI, and then the E. coli BL21 (DE3) strain was transformed using the restriction enzyme product.

<a-3> The obtained transformant was cultured and the expression vector (named pET-FpL_C3KX 8a) was extracted in the same manner as in Comparative Example 1 (1-3) to (1-4). The nucleotide sequence of the vector was analyzed in the same manner as in Comparative Example 1 (1-5).

As a result of sequence analysis, FpL_C3KX was added to the expression vector pET-FpL_C3KX 8a.
It was confirmed that the polynucleotide encoding 8a (SEQ ID NO: 171) was inserted.

<b>FpL_C3KX 8b
<b-1> A polynucleotide containing a nucleotide sequence encoding FpL_C3KX 8b (SEQ ID NO: 174) was produced by introducing mutations using inverse PCR. Mold D
Inverse PCR as NA, pET-FpL_C3KX 7d_A as template DNA
69V, the oligonucleotide set forth in SEQ ID NO: 172 as the PCR Forward Primer, and the oligonucleotide set forth in SEQ ID NO: 173 as the PCR Reverse Primer were used in the same manner as in Example 4(2).

<b-2> The obtained polynucleotide was purified and treated with the restriction enzyme DpnI, and then the E. coli BL21 (DE3) strain was transformed using the restriction enzyme product.

<b-3> The obtained transformant was cultured and the expression vector (named pET-FpL_C3KX 8b) was extracted in the same manner as in Comparative Example 1 (1-3) to (1-4). The nucleotide sequence of the vector was analyzed in the same manner as in Comparative Example 1 (1-5).

As a result of sequence analysis, expression vector pET-FpL_C3KX 8b contained FpL_C3KX.
It was confirmed that the polynucleotide encoding 8b (SEQ ID NO: 174) was inserted.

Example 21 Alkaline stability evaluation of FpL_C3KX 7d amino acid substitution aggregate (1) FpL_C3KX 7d_A69V (SEQ ID NO: 98) obtained in Example 15, and FpL_C3KX 8a (SEQ ID NO: 171) and FpL_ produced in Example 20
A transformant expressing either C3KX 8b (SEQ ID NO: 174) was transformed into Comparative Example 1 (2-
The cells were cultured in the same manner as in 1) to (2-2), and a protein extract was prepared in the manner described in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(2) The supernatant clarified in (1) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(3) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(4) The concentration of NaOH used in the treatment was 1.0M (final concentration 0.5M), and the treatment time was 15
After the alkali treatment in the same manner as in Reference Example 2 (11), except that the time was changed, Reference Example 2
The residual activity was calculated in the same manner as in (12), and the alkali stability was evaluated.

The results are shown in Table 20. FpL_C3KX 8a (SEQ ID NO: 171) and FpL_C3
It was confirmed that KX 8b (SEQ ID NO: 174) had higher residual activity than FpL_C3KX8a_A69V (SEQ ID NO: 98), and the alkaline stability of these mutant immunoglobulin binding proteins was improved.

Example 22 Introduction of amino acid substitutions into the immunoglobulin-binding protein of the present invention Substitutions with amino acid residues with different side chain properties or substitutions with amino acid residues of other domains at positions where the amino acid sequences differ between domains Val14Ala, Gly21Arg, Ile2, which are amino acid substitutions with improved alkali stability obtained by the method of introducing
3Thr, Ala41Arg, Asn44Asp, Asn44Arg, Asn44His
, Glu52Tyr, Gly60Arg and Ile64Leu to FpL_C
3KX 7e (SEQ ID NO: 175). Note that FpL_C3KX 7e has Glu4Gly, Pro6Ser, Lys7Al compared to natural FpL_C3 (SEQ ID NO: 1).
a, Lys13Arg, Lys22Arg, Lys29Ile, Lys29Glu, Ly
s48Arg, Glu49Asp, Asn50Tyr, Tyr53Phe, Asn62T
It is an immunoglobulin-binding protein that introduces amino acid substitutions of yr, Lys67Arg, and Ala69Val.

(1) An expression vector (hereinafter referred to as "pET-FpL_C3K
X 7e”) as PCR Forward Primer and PCR Rev
Inverse PCR was carried out in the same manner as in Example 4(2), except that the combinations of oligonucleotides having the sequences shown in the sequence numbers in Table 21 were used as the combinations of the else primers.

(2) The polynucleotide obtained in (1) was purified and treated with the restriction enzyme DpnI, and the E. coli BL21 (DE3) strain was transformed using the restriction enzyme treatment product.

(3) The obtained transformant was cultured and the expression vector was extracted in the same manner as in Comparative Example 1 (1-4), and the nucleotide sequence of the expression vector was analyzed as in Comparative Example 1 (1-5). It was done in the same way. As a result, it was confirmed that the polynucleotide obtained in (1) was inserted into all expression vectors.

Example 23 Alkaline stability evaluation of FpL_C3KX 7e amino acid substituted product (1) Transformants expressing either FpL_C3KX 7e or FpL_C3KX 7e amino acid substituted product produced in Example 22 (10 types in total) were transformed into Comparative Example 1 ( The cells were cultured in the same manner as in 2-1) to (2-2), and a protein extract was prepared in the manner described in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(2) The supernatant clarified in (1) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(3) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(4) The concentration of NaOH used in the treatment was 1.0M (final concentration 0.5M), and the treatment time was 15
After the alkali treatment in the same manner as in Reference Example 2 (11), except that the time was changed, Reference Example 2
The residual activity was calculated in the same manner as in (12), and the alkali stability was evaluated.
The results are shown in Table 22. All of the FpL_C3KX 7e amino acid substituted products evaluated in this example are FpL_C3 with improved alkaline stability than the natural type FpL_C3 (SEQ ID NO: 1).
It can be said that the alkali stability is improved compared to KX 7e (SEQ ID NO: 175).

Example 24 Accumulation of amino acid substitutions in the immunoglobulin binding protein of the present invention (1) Design of amino acid substitution accumulation Amino acids involved in improving the alkaline stability of the immunoglobulin binding protein revealed in Examples 17 and 23 FpL
_C3KX 7e (SEQ ID NO: 175). Specifically, from <c> to <
Seven types of immunoglobulin-binding proteins shown in i> were designed and produced.
<c> Protein with amino acid substitutions of Ile23Arg and Asn44Arg introduced into FpL_C3KX 7e (SEQ ID NO: 207, named FpL_C3KX 9a)
<d> Protein with amino acid substitutions of Ile23Arg and Asn44His introduced into FpL_C3KX 7e (SEQ ID NO: 208, named FpL_C3KX 9b)
<e> Protein with amino acid substitutions of Ile23Arg and Ile64Leu introduced into FpL_C3KX 7e (SEQ ID NO: 209, named FpL_C3KX 9c)
<f> Protein with Asn44Arg and Ile64Leu amino acid substitutions introduced into FpL_C3KX 7e (SEQ ID NO: 210, named FpL_C3KX 9d)
<g> Protein with Asn44His and Ile64Leu amino acid substitutions introduced into FpL_C3KX 7e (SEQ ID NO: 211, named FpL_C3KX 9e)
<h>For FpL_C3KX 7e, Ile23Arg, Asn44Arg, Lys(
Arg) Protein with amino acid substitutions of 48His and Ile64Leu introduced (SEQ ID NO: 212, named FpL_C3KX 10a)
<i>For FpL_C3KX 7e, Ile23Arg, Asn44His, Lys(
Arg) Protein with amino acid substitutions of 48His and Ile64Leu introduced (SEQ ID NO: 213, named FpL_C3KX 10b)

(2) Preparation of FpL_C3KX 7e amino acid substitution assembly The method for producing the seven types of immunoglobulin binding proteins shown in <c> to <i> above will be described below.

<c>FpL_C3KX 9a
A polynucleotide (SEQ ID NO: 214) encoding <c-1>FpL_C3KX 9a (SEQ ID NO: 207) was synthesized. When synthesizing, a recognition sequence for the restriction enzyme NcoI (5'-CCATGG-3') is placed on the 5' end, and a nucleotide sequence encoding 6 histidine residues (SEQ ID NO: 40) is placed on the 3' end. A stop codon and a recognition sequence for the restriction enzyme HindIII (5'-AAGCTT-3') are respectively added.

<c-2> The polynucleotide synthesized in <c-1> was purified in the same manner as in Comparative Example 1 (1-2).

<c-3> In the same manner as in Comparative Example 1 (1-3), the polynucleotide obtained in <c-2> and plasmid pET-26b previously digested with restriction enzymes NcoI and HindIII are ligated, and then the ligation is performed. E. coli BL21 (DE3) strain was transformed using the product and cultured.

<c-4> The obtained transformant was cultured and plasmid purified in the same manner as in Comparative Example 1 (1-4) to obtain an expression vector (named pET-FpL_C3KX 9a). The nucleotide sequence of was analyzed in the same manner as in Comparative Example 1 (1-5).

As a result of sequence analysis, FpL_C3KX was found in the expression vector pET-FpL_C3KX 9a.
It was confirmed that the polynucleotide (SEQ ID NO: 214) encoding 9a (SEQ ID NO: 207) was inserted.

<d>FpL_C3KX 9b
FpL_C3 as a polynucleotide encoding an immunoglobulin binding protein
Transformants and expression vector (pET-FpL_C3K
X 9b) was obtained. As a result of nucleotide sequence analysis of the expression vector pET-FpL_C3KX 9b, it was confirmed that a polynucleotide (SEQ ID NO: 215) encoding FpL_C3KX 9b (SEQ ID NO: 208) was inserted into pET-FpL_C3KX 9b.

<e>FpL_C3KX 9c
FpL_C3 as a polynucleotide encoding an immunoglobulin binding protein
Transformants and expression vector (pET-FpL_C3K
X 9c) was obtained. As a result of nucleotide sequence analysis of the expression vector pET-FpL_C3KX 9c, it was confirmed that a polynucleotide (SEQ ID NO: 216) encoding FpL_C3KX 9c (SEQ ID NO: 209) was inserted into pET-FpL_C3KX9e.

<f>FpL_C3KX 9d
FpL_C3 as a polynucleotide encoding an immunoglobulin binding protein
Transformants and expression vector (pET-FpL_C3K
X 9d) was obtained. As a result of nucleotide sequence analysis of the expression vector pET-FpL_C3KX 9d, it was confirmed that a polynucleotide (SEQ ID NO: 217) encoding FpL_C3KX 9d (SEQ ID NO: 210) was inserted into pET-FpL_C3KX 9d.

<g>FpL_C3KX 9e
FpL_C3 as a polynucleotide encoding an immunoglobulin binding protein
Transformants and expression vector (pET-FpL_C3K
X 9e) was acquired. As a result of nucleotide sequence analysis of the expression vector pET-FpL_C3KX 9e, it was confirmed that a polynucleotide (SEQ ID NO: 218) encoding FpL_C3KX 9e (SEQ ID NO: 211) was inserted into pET-FpL_C3KX 9e.

<h>FpL_C3KX 10a
FpL_C3 as a polynucleotide encoding an immunoglobulin binding protein
Transformants and expression vector (pET-FpL_C3
KX 10a) was obtained. As a result of nucleotide sequence analysis of the expression vector pET-FpL_C3KX 10a, FpL_C3KX 1 was found in pET-FpL_C3KX 10a.
It was confirmed that the polynucleotide (SEQ ID NO: 219) encoding Oa (SEQ ID NO: 212) was inserted.

<i>FpL_C3KX 10b
FpL_C3 as a polynucleotide encoding an immunoglobulin binding protein
Transformants and expression vector (pET-FpL_C3
KX 10b) was obtained. As a result of nucleotide sequence analysis of the expression vector pET-FpL_C3KX 10b, FpL_C3KX 1 was found in pET-FpL_C3KX 10b.
It was confirmed that a polynucleotide (SEQ ID NO: 220) encoding 0b (SEQ ID NO: 213) was inserted.

Example 25 Acid elution evaluation of FpL_C3KX 8b amino acid substitution product (1) FpL_C3KX 7e (SEQ ID NO: 175) and Fp produced in Example 24
L_C3KX 9a (SEQ ID NO: 207), FpL_C3KX 9b (SEQ ID NO: 208),
FpL_C3KX 9c (SEQ ID NO: 209), FpL_C3KX 9c (SEQ ID NO: 210
), FpL_C3KX 9d (SEQ ID NO: 211), FpL_C3KX 10a (SEQ ID NO: 212), and FpL_C3KX 10b (SEQ ID NO: 213) were transformed into Comparative Examples 1 (1-1) to (1-2). Comparative Example 1 (2-3
A protein extract was prepared by the method described in ). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(2) The supernatant clarified in (1) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(3) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding protein contained in the fractions was quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(4) Each protein was diluted with TBS so that the concentration was equal. The diluted solution was divided into two equal parts, and one part was treated with 0.0
Antibody binding activity was measured after acid treatment with 5M sodium citrate (NaOAc) buffer (pH 3.2) for 5 minutes and addition of TBS (no acid treatment) to the other side. Residual activity was calculated by dividing the antibody binding activity of the acid-treated immunoglobulin binding protein by the antibody binding activity of the acid-untreated immunoglobulin binding protein. The elution rate was calculated by subtracting the residual activity from 1, and the acid elution property was evaluated.

The results are shown in Table 23. FpL_C3KX 9a (SEQ ID NO: 207), FpL_C3KX
9b (SEQ ID NO: 208), FpL_C3KX 9c (SEQ ID NO: 209), FpL_C3
KX 9d (SEQ ID NO: 210), FpL_C3KX 9e (SEQ ID NO: 211), FpL_
C3KX 10a (SEQ ID NO: 212) and FpL_C3KX 10b (SEQ ID NO: 213)
) has a higher elution rate compared to FpL_C3KX 7e (SEQ ID NO: 175),
It was confirmed that the acid elution properties of these mutant immunoglobulin-binding proteins were improved. Among them FpL_C3KX 9a (SEQ ID NO: 207) and FpL_C3KX
It can be seen that 10a (SEQ ID NO: 212) has particularly improved acid dissolution properties.

Example 26 Mutation introduction into FpL_C3KX 7e and library construction (Part 3)
(1) Vector pET-FpL expressing FpL_C3KX 7e (SEQ ID NO: 175)
A saturated substitution library for the 15th and 34th amino acid residues was created using _C3KX 7e as a template. The primer was 22c-Trick as in Example 1 (2).
According to the method, an appropriate mixed base was placed at the site of mutation introduction, and it was designed to perform inverse PCR centered on the site of mutation introduction (SEQ ID NOS: 221 to 232). These primers were mixed as a set of 6 primers per substitution in Table 1 and Table 24, and PCR Pri
A mer mixture (Forward/Reverse primer mix) was prepared.

(2) Example 2 (2-2) except that pET-FpL_C3KX 7e was used as the template DNA
Site-directed mutagenesis was performed by inverse PCR in the same manner as described above.

(3) After purifying the obtained PCR product, E. coli BL21 (DE3) strain was transformed using the reaction solution, and cultured in LB plate medium containing 50 μg/mL kanamycin (37°C, 16
The colonies formed on the plate were used as a site-specific mutant library.

Example 27 Screening for FpL_C3KX 7e amino acid substitution product (Part 3)
(1) A site-specific amino acid substitution library (transformant) prepared using pET-FpL_C3KX 7e (transformant) and the random mutant library (transformant) prepared in Example 26 was used in Example 2 (transformant). ) to Example 15 (2) after culturing in the same manner as (2).
The alkali treatment described in .

(2) The antibody binding activity of the immunoglobulin-binding protein when treated with alkali was measured by the ELISA method described in Example 2 (4), and the antibody binding activity of the immunoglobulin-binding protein when treated with alkaline was determined by the ELISA method described in Example 2 (4). Residual activity was calculated by dividing the binding activity by the antibody binding activity of the immunoglobulin binding protein without alkali treatment.

(3) Approximately 200 transformants were evaluated, and transformants expressing an immunoglobulin-binding protein with improved alkaline stability compared to FpL_C3KX 7e (SEQ ID NO: 175) were selected from among them.

(4) Cultivate the selected transformant and apply QIAprep Spin Miniprep.
An expression vector was prepared using a kit (manufactured by QIAGEN).

(5) Analyze the nucleotide sequence of the polynucleotide region encoding the immunoglobulin-binding protein inserted into the obtained expression vector by the method described in Comparative Example 1 (1-5), and identify the amino acid mutation locations. Identified.

(6) A transformant expressing the immunoglobulin binding protein selected in (3) or a transformant expressing pET-FpL_C3KX 7e (SEQ ID NO: 175) was used in Comparative Example 1.
Culture was performed in the same manner as in (2-1) to (2-2), and a protein extract was prepared in the same manner as in Comparative Example 1 (2-3). The extract was centrifuged, and the resulting supernatant was passed through a filter for clarification.

(7) The supernatant clarified in (6) was purified by the method described in Example 7 (7), and a fraction corresponding to immunoglobulin-binding protein was collected.

(8) The absorbance of the collected fractions was measured using a spectrophotometer, and the immunoglobulin-binding proteins contained in the fractions were quantified. SDS-PAGE was also performed, and it was confirmed that the selected immunoglobulin-binding protein was purified to a high degree of purity.

(9) Acid elubility was evaluated in the same manner as in Example 25 (4).

The results are shown in Table 25. In the amino acid sequence set forth in SEQ ID NO: 175, at least Asn
15Val, Glu34Asp, Glu34Phe, Glu34Leu and Glu34
Immunoglobulin-binding proteins with one or more amino acid substitutions selected from Val have a higher elution rate than FpL_C3KX 7e (SEQ ID NO: 175), and acid elution of these mutant immunoglobulin-binding proteins It was confirmed that the performance was improved.

Claims (10)

A protein having immunoglobulin binding activity , comprising the amino acid sequence set forth in any one of SEQ ID NOs : 79, 86, 96, 171, 175, 207 and 212. A polynucleotide encoding the protein according to claim 1 . An expression vector comprising the polynucleotide according to claim 2 . A genetically modified host comprising the following (A) or (B):
(A) a polynucleotide encoding the protein according to claim 1 ;
(B) An expression vector comprising a polynucleotide encoding the protein according to claim 1 . The genetically modified host according to claim 4 , wherein the host is Escherichia coli. A step of culturing a genetically modified host containing a polynucleotide encoding the protein according to claim 1 or an expression vector containing the polynucleotide to express the protein, and collecting the expressed protein. A method for producing an immunoglobulin-binding protein, comprising the steps of: The production method according to claim 6 , wherein the host is Escherichia coli. An immunoglobulin adsorbent comprising an insoluble carrier and the protein according to claim 1 immobilized on the insoluble carrier. A step of adding a solution containing immunoglobulin to a column packed with the adsorbent according to claim 8 to adsorb the immunoglobulin to the adsorbent, and a step of eluting the immunoglobulin adsorbed to the adsorbent by changing the pH. A method for separating immunoglobulins contained in the solution, comprising: 10. The method of claim 9 , wherein the pH change is a decrease in pH.